51
|
Guo R, Li S, Xia H, Feng Z, Tang Q, Peng C. Effects of Myeloperoxidase on Methicillin-Resistant Staphylococcus aureus-Colonized Burn Wounds in Rats. Adv Wound Care (New Rochelle) 2019; 8:271-280. [PMID: 31737417 DOI: 10.1089/wound.2018.0865] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2018] [Accepted: 01/14/2019] [Indexed: 01/10/2023] Open
Abstract
Objective: To achieve better therapeutic results in burn wound infections and to examine alternatives to antibiotics, we designed this study to elaborate the role of myeloperoxidase (MPO) on infected burn wounds in rats. Approach: We compared chemical properties as well as bacteriostatic ability of MPO in different concentrations with NeutroPhase. Subsequently, we applied MPO (MPO group), NeutroPhase (NeutroPhase group), NaCl+H2O2 (NaCl+H2O2 group), or NaCl (control group) on rat dorsal burn wounds inoculated with methicillin-resistant Staphylococcus aureus (MRSA). Their effects on MRSA-colonized wounds were evaluated by microscopy, histologic section, and Western blot. Results: MPO produced more H+ and HClO-, leading to a more acidic environment. Moreover, MPO inhibited the growth of MRSA more intensely after 6 h of inoculation ex vivo. In vivo the open wound rate in the MPO group was significantly lower, while the contraction rate and epithelialization rate of MPO group were higher than that of the control group, NaCl+H2O2 group, and NeutroPhase group on day 20. The hematoxylin and eosin staining of MPO group showed better wound healing than other groups. More vascular endothelial growth factor (VEGF) was expressed in wound tissue of MPO group by Western blot. Innovation: This is the first study to use MPO for MRSA-colonized burn wound therapy. Conclusion: MPO displayed more effective bacteriostatic ability, possibly beneficial for MRSA-colonized wound healing.
Collapse
Affiliation(s)
- Ren Guo
- Department of Plastic Surgery, the Third Xiangya Hospital, Central South University, Changsha, China
- Department of Pharmacy, the Third Xiangya Hospital, Central South University, Changsha, China
| | - Shuaihua Li
- Department of Cosmetic and Plastic Surgery, the First People's Hospital of Chenzhou, Chenzhou, China
| | - Hansong Xia
- Department of Orthopedics, the Third Xiangya Hospital, Central South University, Changsha, China
| | - Zhicai Feng
- Department of Plastic Surgery, the Third Xiangya Hospital, Central South University, Changsha, China
| | - Qiyu Tang
- Department of Plastic Surgery, the Third Xiangya Hospital, Central South University, Changsha, China
| | - Cheng Peng
- Department of Plastic Surgery, the Third Xiangya Hospital, Central South University, Changsha, China
| |
Collapse
|
52
|
Xie Z, Kuhns DB, Gu X, Otu HH, Libermann TA, Gallin JI, Parikh SM, Druey KM. Neutrophil activation in systemic capillary leak syndrome (Clarkson disease). J Cell Mol Med 2019; 23:5119-5127. [PMID: 31210423 PMCID: PMC6653644 DOI: 10.1111/jcmm.14381] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2018] [Revised: 04/04/2019] [Accepted: 04/29/2019] [Indexed: 11/30/2022] Open
Abstract
Systemic capillary leak syndrome (SCLS; Clarkson disease) is a rare orphan disorder characterized by transient yet recurrent episodes of hypotension and peripheral oedema due to diffuse vascular leakage of fluids and proteins into soft tissues. Humoral mediators, cellular responses and genetic features accounting for the clinical phenotype of SCLS are virtually unknown. Here, we searched for factors altered in acute SCLS plasma relative to matched convalescent samples using multiplexed aptamer‐based proteomic screening. Relative amounts of 612 proteins were changed greater than twofold and 81 proteins were changed at least threefold. Among the most enriched proteins in acute SCLS plasma were neutrophil granule components including bactericidal permeability inducing protein, myeloperoxidase and matrix metalloproteinase 8. Neutrophils isolated from blood of subjects with SCLS or healthy controls responded similarly to routine pro‐inflammatory mediators. However, acute SCLS sera activated neutrophils relative to remission sera. Activated neutrophil supernatants increased permeability of endothelial cells from both controls and SCLS subjects equivalently. Our results suggest systemic neutrophil degranulation during SCLS acute flares, which may contribute to the clinical manifestations of acute vascular leak.
Collapse
Affiliation(s)
- Zhihui Xie
- Lung and Vascular Inflammation Section, Laboratory of Allergic Diseases, NIAID/NIH, Bethesda, Maryland
| | - Douglas B Kuhns
- Neutrophil Monitoring Laboratory, NCI/NIH, Frederick, Maryland
| | - Xuesong Gu
- Genomics, Proteomics, Bioinformatics and Systems Biology Center, Division of Interdisciplinary Medicine and Biotechnology, Beth Israel Deaconess Medical Center & Harvard Medical School, Boston, Massachusetts
| | - Hasan H Otu
- Department of Electrical and Computer Engineering, University of Nebraska, Lincoln, Nebraska
| | - Towia A Libermann
- Genomics, Proteomics, Bioinformatics and Systems Biology Center, Division of Interdisciplinary Medicine and Biotechnology, Beth Israel Deaconess Medical Center & Harvard Medical School, Boston, Massachusetts
| | - John I Gallin
- Clinical Pathophysiology Section, NIAID/NIH, Bethesda, Maryland
| | - Samir M Parikh
- Department of Medicine, Division of Nephrology and Center for Vascular Biology Research, Beth Israel Deaconess Medical Center & Harvard Medical School, Boston, Massachusetts
| | - Kirk M Druey
- Lung and Vascular Inflammation Section, Laboratory of Allergic Diseases, NIAID/NIH, Bethesda, Maryland
| |
Collapse
|
53
|
Chikusetsusaponin V attenuates lipopolysaccharide-induced acute lung injury in mice by modulation of the NF-κB and LXRα. Int Immunopharmacol 2019; 70:174-179. [DOI: 10.1016/j.intimp.2019.02.023] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2018] [Revised: 01/10/2019] [Accepted: 02/13/2019] [Indexed: 12/14/2022]
|
54
|
Sodium thiocyanate treatment attenuates atherosclerotic plaque formation and improves endothelial regeneration in mice. PLoS One 2019; 14:e0214476. [PMID: 30939159 PMCID: PMC6445437 DOI: 10.1371/journal.pone.0214476] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2018] [Accepted: 03/13/2019] [Indexed: 01/01/2023] Open
Abstract
Introduction Atherosclerotic plaque formation is an inflammatory process that involves the recruitment of neutrophil granulocytes and the generation of reactive oxygen species (ROS). ROS formation by myeloperoxidase, a key enzyme in H2O2 degradation, can be modulated by addition of sodium thiocyanate (NaSCN). However, the therapeutic use of NaSCN to counteract atherogenesis has been controversial, because MPO oxidizes NaSCN to hypothiocyanous acid, which is a reactive oxygen species itself. Therefore, this study aimed to investigate the effect of NaSCN treatment on atherogenesis in vivo. Methods Apolipoprotein E knockout (ApoE−/−) mice on western-diet were treated with NaSCN for 8 weeks. Blood levels of total cholesterol, IL-10, and IL-6 were measured. Aortic roots from these mice were analyzed histologically to quantify plaque formation, monocyte, and neutrophil granulocyte infiltration. Oxidative damage was evaluated via an L-012 chemiluminescence assay and staining for chlorotyrosine in the aortic walls. Endothelial function was assessed by use of endothelium-dependent vasodilation in isolated aortic rings. Neointima formation was evaluated in wild-type mice following wire injury of the carotid artery. Results NaSCN treatment of ApoE-/- mice lead to a reduction of atherosclerotic plaque size in the aortic roots but had no effect on monocyte or granulocyte infiltration. Serum levels of the pro-inflammatory cytokine IL-6 decreased whereas anti-inflammatory IL-10 increased upon NaSCN treatment. In our experiments, we found oxidative damage to be reduced and the endothelial function to be improved in the NaSCN-treated group. Additionally, NaSCN inhibited neointima formation. Conclusion NaSCN has beneficial effects on various stages of atherosclerotic plaque development in mice.
Collapse
|
55
|
Gu Y, Liang Y, Bai J, Wu W, Lin Q, Wu J. Spent hen-derived ACE inhibitory peptide IWHHT shows antioxidative and anti-inflammatory activities in endothelial cells. J Funct Foods 2019. [DOI: 10.1016/j.jff.2018.12.006] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
56
|
Hoffmann A, Pfeil J, Mueller AK, Jin J, Deumelandt K, Helluy X, Wang C, Heiland S, Platten M, Chen JW, Bendszus M, Breckwoldt MO. MRI of Iron Oxide Nanoparticles and Myeloperoxidase Activity Links Inflammation to Brain Edema in Experimental Cerebral Malaria. Radiology 2018; 290:359-367. [PMID: 30615566 DOI: 10.1148/radiol.2018181051] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Purpose To investigate the association of inflammation and brain edema in a cerebral malaria (CM) mouse model with a combination of bis-5-hydroxy-tryptamide-diethylenetriaminepentaacetate gadolinium, referred to as MPO-Gd, and cross-linked iron oxide nanoparticle (CLIO-NP) imaging. Materials and Methods Female wild-type (n = 23) and myeloperoxidase (MPO) knock-out (n = 5) mice were infected with the Plasmodium berghei ANKA strain from May 2016 to July 2018. Seven healthy mice served as control animals. At a Rapid Murine Coma and Behavioral Scale (RMCBS) score of less than 15, mice underwent MRI at 9.4 T and received gadodiamide, MPO-Gd, or CLIO-NPs. T1-weighted MRI was used to assess MPO activity, and T2*-weighted MRI was used to track CLIO-NPs. Immunofluorescent staining and flow cytometric analyses characterized CLIO-NPs, MPO, endothelial cells, and leukocytes. An unpaired, two-tailed Student t test was used to compare groups; Spearman correlation analysis was used to determine the relationship of imaging parameters to clinical severity. Results MPO-Gd enhancement occurred in inflammatory CM hotspots (olfactory bulb > rostral migratory stream > brainstem > cortex, P < .05 for all regions compared with control mice; mean olfactory bulb signal intensity ratio: 1.40 ± 0.07 vs 0.96 ± 0.01, P < .01). The enhancement was reduced in MPO knockout mice (mean signal intensity ratio at 60 minutes: 1.13 ± 0.04 vs 1.40 ± 0.07 in CM, P < .05). Blood-brain barrier compromise was suggested by parenchymal gadolinium enhancement, leukocyte recruitment, and endothelial activation. CLIO-NPs accumulated mainly intravascularly and at the vascular endothelium. CLIO-NPs were also found in the choroid plexus, indicating inflammation of the ventricular system. Blood-cerebrospinal fluid barrier breakdown showed correlation with brain swelling (r2: 0.55, P < .01) and RMCBS score (r2: 0.75, P < .001). Conclusion Iron oxide nanoparticle imaging showed strong inflammatory involvement of the microvasculature in a murine model of cerebral malaria. Furthermore, bis-5-hydroxy-tryptamide-diethylenetriaminepentaacetate gadolinium imaging depicted parenchymal and intraventricular inflammation. This combined molecular imaging approach links vascular inflammation to breakdown of the blood-brain barrier and blood-cerebrospinal fluid barrier that correlate with global brain edema and disease severity. © RSNA, 2018 Online supplemental material is available for this article. See also the editorial by Kiessling in this issue.
Collapse
Affiliation(s)
- Angelika Hoffmann
- From the Department of Neuroradiology (A.H., J.J., X.H., S.H., M.B., M.O.B.), Centre for Infectious Diseases, Parasitology Unit (J.P., A.K.M.), and Center for Childhood and Adolescent Medicine, General Pediatrics (J.P.), University Hospital Heidelberg, University of Heidelberg, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany; German Centre for Infection Research (DZIF), Heidelberg, Germany (J.P., A.K.M.); DKTK Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany (K.D., M.P., M.O.B.); NeuroImaging Centre Research, Department of Neuroscience, Ruhr-University Bochum, Bochum, Germany (X.H.); Center for Systems Biology and Institute for Innovation in Imaging (C.W., J.W.C.) and Division of Neuroradiology, Department of Radiology (J.W.C.), Massachusetts General Hospital, Harvard Medical School, Boston, Mass; and Neurology Clinic, University Hospital Mannheim, Mannheim, Germany (M.P.)
| | - Johannes Pfeil
- From the Department of Neuroradiology (A.H., J.J., X.H., S.H., M.B., M.O.B.), Centre for Infectious Diseases, Parasitology Unit (J.P., A.K.M.), and Center for Childhood and Adolescent Medicine, General Pediatrics (J.P.), University Hospital Heidelberg, University of Heidelberg, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany; German Centre for Infection Research (DZIF), Heidelberg, Germany (J.P., A.K.M.); DKTK Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany (K.D., M.P., M.O.B.); NeuroImaging Centre Research, Department of Neuroscience, Ruhr-University Bochum, Bochum, Germany (X.H.); Center for Systems Biology and Institute for Innovation in Imaging (C.W., J.W.C.) and Division of Neuroradiology, Department of Radiology (J.W.C.), Massachusetts General Hospital, Harvard Medical School, Boston, Mass; and Neurology Clinic, University Hospital Mannheim, Mannheim, Germany (M.P.)
| | - Ann-Kristin Mueller
- From the Department of Neuroradiology (A.H., J.J., X.H., S.H., M.B., M.O.B.), Centre for Infectious Diseases, Parasitology Unit (J.P., A.K.M.), and Center for Childhood and Adolescent Medicine, General Pediatrics (J.P.), University Hospital Heidelberg, University of Heidelberg, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany; German Centre for Infection Research (DZIF), Heidelberg, Germany (J.P., A.K.M.); DKTK Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany (K.D., M.P., M.O.B.); NeuroImaging Centre Research, Department of Neuroscience, Ruhr-University Bochum, Bochum, Germany (X.H.); Center for Systems Biology and Institute for Innovation in Imaging (C.W., J.W.C.) and Division of Neuroradiology, Department of Radiology (J.W.C.), Massachusetts General Hospital, Harvard Medical School, Boston, Mass; and Neurology Clinic, University Hospital Mannheim, Mannheim, Germany (M.P.)
| | - Jessica Jin
- From the Department of Neuroradiology (A.H., J.J., X.H., S.H., M.B., M.O.B.), Centre for Infectious Diseases, Parasitology Unit (J.P., A.K.M.), and Center for Childhood and Adolescent Medicine, General Pediatrics (J.P.), University Hospital Heidelberg, University of Heidelberg, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany; German Centre for Infection Research (DZIF), Heidelberg, Germany (J.P., A.K.M.); DKTK Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany (K.D., M.P., M.O.B.); NeuroImaging Centre Research, Department of Neuroscience, Ruhr-University Bochum, Bochum, Germany (X.H.); Center for Systems Biology and Institute for Innovation in Imaging (C.W., J.W.C.) and Division of Neuroradiology, Department of Radiology (J.W.C.), Massachusetts General Hospital, Harvard Medical School, Boston, Mass; and Neurology Clinic, University Hospital Mannheim, Mannheim, Germany (M.P.)
| | - Katrin Deumelandt
- From the Department of Neuroradiology (A.H., J.J., X.H., S.H., M.B., M.O.B.), Centre for Infectious Diseases, Parasitology Unit (J.P., A.K.M.), and Center for Childhood and Adolescent Medicine, General Pediatrics (J.P.), University Hospital Heidelberg, University of Heidelberg, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany; German Centre for Infection Research (DZIF), Heidelberg, Germany (J.P., A.K.M.); DKTK Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany (K.D., M.P., M.O.B.); NeuroImaging Centre Research, Department of Neuroscience, Ruhr-University Bochum, Bochum, Germany (X.H.); Center for Systems Biology and Institute for Innovation in Imaging (C.W., J.W.C.) and Division of Neuroradiology, Department of Radiology (J.W.C.), Massachusetts General Hospital, Harvard Medical School, Boston, Mass; and Neurology Clinic, University Hospital Mannheim, Mannheim, Germany (M.P.)
| | - Xavier Helluy
- From the Department of Neuroradiology (A.H., J.J., X.H., S.H., M.B., M.O.B.), Centre for Infectious Diseases, Parasitology Unit (J.P., A.K.M.), and Center for Childhood and Adolescent Medicine, General Pediatrics (J.P.), University Hospital Heidelberg, University of Heidelberg, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany; German Centre for Infection Research (DZIF), Heidelberg, Germany (J.P., A.K.M.); DKTK Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany (K.D., M.P., M.O.B.); NeuroImaging Centre Research, Department of Neuroscience, Ruhr-University Bochum, Bochum, Germany (X.H.); Center for Systems Biology and Institute for Innovation in Imaging (C.W., J.W.C.) and Division of Neuroradiology, Department of Radiology (J.W.C.), Massachusetts General Hospital, Harvard Medical School, Boston, Mass; and Neurology Clinic, University Hospital Mannheim, Mannheim, Germany (M.P.)
| | - Cuihua Wang
- From the Department of Neuroradiology (A.H., J.J., X.H., S.H., M.B., M.O.B.), Centre for Infectious Diseases, Parasitology Unit (J.P., A.K.M.), and Center for Childhood and Adolescent Medicine, General Pediatrics (J.P.), University Hospital Heidelberg, University of Heidelberg, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany; German Centre for Infection Research (DZIF), Heidelberg, Germany (J.P., A.K.M.); DKTK Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany (K.D., M.P., M.O.B.); NeuroImaging Centre Research, Department of Neuroscience, Ruhr-University Bochum, Bochum, Germany (X.H.); Center for Systems Biology and Institute for Innovation in Imaging (C.W., J.W.C.) and Division of Neuroradiology, Department of Radiology (J.W.C.), Massachusetts General Hospital, Harvard Medical School, Boston, Mass; and Neurology Clinic, University Hospital Mannheim, Mannheim, Germany (M.P.)
| | - Sabine Heiland
- From the Department of Neuroradiology (A.H., J.J., X.H., S.H., M.B., M.O.B.), Centre for Infectious Diseases, Parasitology Unit (J.P., A.K.M.), and Center for Childhood and Adolescent Medicine, General Pediatrics (J.P.), University Hospital Heidelberg, University of Heidelberg, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany; German Centre for Infection Research (DZIF), Heidelberg, Germany (J.P., A.K.M.); DKTK Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany (K.D., M.P., M.O.B.); NeuroImaging Centre Research, Department of Neuroscience, Ruhr-University Bochum, Bochum, Germany (X.H.); Center for Systems Biology and Institute for Innovation in Imaging (C.W., J.W.C.) and Division of Neuroradiology, Department of Radiology (J.W.C.), Massachusetts General Hospital, Harvard Medical School, Boston, Mass; and Neurology Clinic, University Hospital Mannheim, Mannheim, Germany (M.P.)
| | - Michael Platten
- From the Department of Neuroradiology (A.H., J.J., X.H., S.H., M.B., M.O.B.), Centre for Infectious Diseases, Parasitology Unit (J.P., A.K.M.), and Center for Childhood and Adolescent Medicine, General Pediatrics (J.P.), University Hospital Heidelberg, University of Heidelberg, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany; German Centre for Infection Research (DZIF), Heidelberg, Germany (J.P., A.K.M.); DKTK Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany (K.D., M.P., M.O.B.); NeuroImaging Centre Research, Department of Neuroscience, Ruhr-University Bochum, Bochum, Germany (X.H.); Center for Systems Biology and Institute for Innovation in Imaging (C.W., J.W.C.) and Division of Neuroradiology, Department of Radiology (J.W.C.), Massachusetts General Hospital, Harvard Medical School, Boston, Mass; and Neurology Clinic, University Hospital Mannheim, Mannheim, Germany (M.P.)
| | - John W Chen
- From the Department of Neuroradiology (A.H., J.J., X.H., S.H., M.B., M.O.B.), Centre for Infectious Diseases, Parasitology Unit (J.P., A.K.M.), and Center for Childhood and Adolescent Medicine, General Pediatrics (J.P.), University Hospital Heidelberg, University of Heidelberg, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany; German Centre for Infection Research (DZIF), Heidelberg, Germany (J.P., A.K.M.); DKTK Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany (K.D., M.P., M.O.B.); NeuroImaging Centre Research, Department of Neuroscience, Ruhr-University Bochum, Bochum, Germany (X.H.); Center for Systems Biology and Institute for Innovation in Imaging (C.W., J.W.C.) and Division of Neuroradiology, Department of Radiology (J.W.C.), Massachusetts General Hospital, Harvard Medical School, Boston, Mass; and Neurology Clinic, University Hospital Mannheim, Mannheim, Germany (M.P.)
| | - Martin Bendszus
- From the Department of Neuroradiology (A.H., J.J., X.H., S.H., M.B., M.O.B.), Centre for Infectious Diseases, Parasitology Unit (J.P., A.K.M.), and Center for Childhood and Adolescent Medicine, General Pediatrics (J.P.), University Hospital Heidelberg, University of Heidelberg, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany; German Centre for Infection Research (DZIF), Heidelberg, Germany (J.P., A.K.M.); DKTK Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany (K.D., M.P., M.O.B.); NeuroImaging Centre Research, Department of Neuroscience, Ruhr-University Bochum, Bochum, Germany (X.H.); Center for Systems Biology and Institute for Innovation in Imaging (C.W., J.W.C.) and Division of Neuroradiology, Department of Radiology (J.W.C.), Massachusetts General Hospital, Harvard Medical School, Boston, Mass; and Neurology Clinic, University Hospital Mannheim, Mannheim, Germany (M.P.)
| | - Michael O Breckwoldt
- From the Department of Neuroradiology (A.H., J.J., X.H., S.H., M.B., M.O.B.), Centre for Infectious Diseases, Parasitology Unit (J.P., A.K.M.), and Center for Childhood and Adolescent Medicine, General Pediatrics (J.P.), University Hospital Heidelberg, University of Heidelberg, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany; German Centre for Infection Research (DZIF), Heidelberg, Germany (J.P., A.K.M.); DKTK Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany (K.D., M.P., M.O.B.); NeuroImaging Centre Research, Department of Neuroscience, Ruhr-University Bochum, Bochum, Germany (X.H.); Center for Systems Biology and Institute for Innovation in Imaging (C.W., J.W.C.) and Division of Neuroradiology, Department of Radiology (J.W.C.), Massachusetts General Hospital, Harvard Medical School, Boston, Mass; and Neurology Clinic, University Hospital Mannheim, Mannheim, Germany (M.P.)
| |
Collapse
|
57
|
Ismaeel A, Lavado R, Smith RS, Eidson JL, Sawicki I, Kirk JS, Bohannon WT, Koutakis P. Effects of Limb Revascularization Procedures on Oxidative Stress. J Surg Res 2018; 232:503-509. [DOI: 10.1016/j.jss.2018.07.024] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2018] [Revised: 06/27/2018] [Accepted: 07/11/2018] [Indexed: 12/20/2022]
|
58
|
Zheng GR, Chen B, Shen J, Qiu SZ, Yin HM, Mao W, Wang HX, Gao JB. Serum myeloperoxidase concentrations for outcome prediction in acute intracerebral hemorrhage. Clin Chim Acta 2018; 487:330-336. [PMID: 30347182 DOI: 10.1016/j.cca.2018.10.026] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2018] [Revised: 10/17/2018] [Accepted: 10/18/2018] [Indexed: 02/01/2023]
Abstract
BACKGROUND Oxidative stress is related to brain injury after spontaneous intracerebral hemorrhage (ICH). Myeloperoxidase (MPO) is a potent oxidizing enzyme. We tested the hypothesis that serum MPO concentrations are increased after ICH and they correlate with stroke severity and outcome. METHODS Serum MPO concentrations were measured in 128 ICH patients and 128 controls. Odds ratios of dependent variables, including early neurological deterioration, hematoma growth, 1-week mortality, 6-month mortality, 6-month unfavorable outcome (modified Rankin Scale score > 2) and 6-month overall survival, were calculated and adjusted for age, sex, hematoma volume, National Institutes of Health Stroke Scale (NIHSS) score and vascular risk factors. RESULTS As compared to the controls, the patients had significantly increased serum MPO concentrations. MPO concentrations of the ICH patients were strongly correlated with hematoma volume and NIHSS scores. Serum MPO were independently associated with the above-mentioned study points. Its area under receiver operating characteristic curve was equivalent to those of hematoma volume and NIHSS score. Moreover, serum MPO significantly improved the discriminatory ability of hematoma and NIHSS in predicting 6-month mortality and unfavorable outcome. CONCLUSIONS Serum MPO concentrations rise in ICH patients and there is a correlation between MPO concentrations and severity or prognosis.
Collapse
Affiliation(s)
- Guan-Rong Zheng
- Department of Neurosurgery, The First People's Hospital of Fuyang District of Hangzhou City, 429 Beihuan Road, Fuyang District, Hangzhou 311400, China
| | - Bin Chen
- Department of Neurosurgery, The First People's Hospital of Fuyang District of Hangzhou City, 429 Beihuan Road, Fuyang District, Hangzhou 311400, China
| | - Jia Shen
- Department of Neurosurgery, The First People's Hospital of Fuyang District of Hangzhou City, 429 Beihuan Road, Fuyang District, Hangzhou 311400, China
| | - Shen-Zhong Qiu
- Department of Neurosurgery, The First People's Hospital of Fuyang District of Hangzhou City, 429 Beihuan Road, Fuyang District, Hangzhou 311400, China.
| | - Huai-Ming Yin
- Department of Neurosurgery, The First People's Hospital of Fuyang District of Hangzhou City, 429 Beihuan Road, Fuyang District, Hangzhou 311400, China
| | - Wei Mao
- Department of Neurosurgery, The First People's Hospital of Fuyang District of Hangzhou City, 429 Beihuan Road, Fuyang District, Hangzhou 311400, China
| | - Hong-Xiang Wang
- Department of Neurology, The First People's Hospital of Fuyang District of Hangzhou City, 429 Beihuan Road, Fuyang District, Hangzhou 311400, China
| | - Jian-Bo Gao
- Department of Emergency Medicine, The First People's Hospital of Fuyang District of Hangzhou City, 429 Beihuan Road, Fuyang District, Hangzhou 311400, China
| |
Collapse
|
59
|
Peiminine Protects against Lipopolysaccharide-Induced Mastitis by Inhibiting the AKT/NF-κB, ERK1/2 and p38 Signaling Pathways. Int J Mol Sci 2018; 19:ijms19092637. [PMID: 30200569 PMCID: PMC6164606 DOI: 10.3390/ijms19092637] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2018] [Revised: 09/03/2018] [Accepted: 09/05/2018] [Indexed: 02/06/2023] Open
Abstract
Peiminine, an alkaloid extracted from Fritillaria plants, has been reported to have potent anti-inflammatory properties. However, the anti-inflammatory effect of peiminine on a mouse lipopolysaccharide (LPS)-induced mastitis model remains to be elucidated. The purpose of this experiment was to investigate the effect of peiminine on LPS-induced mastitis in mice. LPS was injected through the canals of the mammary gland to generate the mouse LPS-induced mastitis model. Peiminine was administered intraperitoneally 1 h before and 12 h after the LPS injection. In vitro, mouse mammary epithelial cells (mMECs) were pretreated with different concentrations of peiminine for 1 h and were then stimulated with LPS. The mechanism of peiminine on mastitis was studied by hematoxylin-eosin staining (H&E) staining, western blotting, and enzyme-linked immunosorbent assay (ELISA). The results showed that peiminine significantly decreased the histopathological impairment of the mammary gland in vivo and reduced the production of pro-inflammatory mediators in vivo and in vitro. Furthermore, peiminine inhibited the phosphorylation of the protein kinase B (AKT)/ nuclear factor-κB (NF-κB), extracellular regulated protein kinase (ERK1/2), and p38 signaling pathways both in vivo and in vitro. All the results suggested that peiminine exerted potent anti-inflammatory effects on LPS-induced mastitis in mice. Therefore, peiminine might be a potential therapeutic agent for mastitis.
Collapse
|
60
|
Tripathi P, Singh A, Sanyal S, Yadav SK, Nigam K. Association of polymorphism in P16 and myeloperoxidase genes with susceptibility to oral lesions in North Indian population. Meta Gene 2018. [DOI: 10.1016/j.mgene.2018.05.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/16/2022] Open
|
61
|
Tao JH, Duan JA, Zhang W, Jiang S, Guo JM, Wei DD. Polysaccharides From Chrysanthemum morifolium Ramat Ameliorate Colitis Rats via Regulation of the Metabolic Profiling and NF-κ B/TLR4 and IL-6/JAK2/STAT3 Signaling Pathways. Front Pharmacol 2018; 9:746. [PMID: 30042683 PMCID: PMC6049019 DOI: 10.3389/fphar.2018.00746] [Citation(s) in RCA: 55] [Impact Index Per Article: 9.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2018] [Accepted: 06/19/2018] [Indexed: 12/22/2022] Open
Abstract
Studies have indicated that Chrysanthemum polysaccharides (CP) could prominently ameliorate colitis rats, but its possible mechanism remains unclear. In this study, the underlying mechanism of CP was explored by the metabolic profiling analysis and correlated signaling pathways. TNBS/ethanol induced colitis was used to investigate the intervention efficacy following oral administration of CP. The levels of cytokines such as TNF-α, IL-6, IFN-γ and IL-1β, and the activities of SOD, MPO, and MDA were determined. We also performed western-blot for p65, TLR4, p-JAK2, and STAT3 protein expression in the colon tissue to probe their mechanisms of correlated signaling pathways. What’s more, the metabolic changes in plasma and urine from colitis rats were investigated based on UPLC-Q-TOF/MS combined with MetabolynxTM software. The potential biomarkers and metabolic pathways were also tentatively confirmed. The metabolic profiles of plasma and urine were clearly improved in model rats after oral administration of CP. Thirty-two (17 in serum and 15 in urine) potential biomarkers were identified. The endogenous metabolites were mainly involved in linoleic acid, retinol, arachidonic acid, glycerophospholipid and primary bile acid metabolism in plasma, and nicotinate and nicotinamide, ascorbate and aldarate, histidine and β-alanine metabolism in urine. After polysaccharides intervention, these markers turned back to normal level at some extent. Meanwhile, the elevated expression levels of pp65, TLR4, p-STAT3, and p-JAK2 were significantly decreased after treatment. Results suggested that CP would be a potential prebiotics for alleviation of TNBS-induced colitis. The study paved the way for the further exploration of the pathogenesis, early diagnosis and curative drug development of the colitis.
Collapse
Affiliation(s)
- Jin-Hua Tao
- School of Pharmacy, Nantong University, Nantong, China
| | - Jin-Ao Duan
- Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, Nanjing University of Chinese Medicine, Nanjing, China
| | - Wei Zhang
- School of Pharmacy, Nantong University, Nantong, China
| | - Shu Jiang
- Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, Nanjing University of Chinese Medicine, Nanjing, China
| | - Jian-Ming Guo
- Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, Nanjing University of Chinese Medicine, Nanjing, China
| | - Dan-Dan Wei
- Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, Nanjing University of Chinese Medicine, Nanjing, China
| |
Collapse
|
62
|
Klinke A, Berghausen E, Friedrichs K, Molz S, Lau D, Remane L, Berlin M, Kaltwasser C, Adam M, Mehrkens D, Mollenhauer M, Manchanda K, Ravekes T, Heresi GA, Aytekin M, Dweik RA, Hennigs JK, Kubala L, Michaëlsson E, Rosenkranz S, Rudolph TK, Hazen SL, Klose H, Schermuly RT, Rudolph V, Baldus S. Myeloperoxidase aggravates pulmonary arterial hypertension by activation of vascular Rho-kinase. JCI Insight 2018; 3:97530. [PMID: 29875311 PMCID: PMC6124430 DOI: 10.1172/jci.insight.97530] [Citation(s) in RCA: 39] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2017] [Accepted: 04/19/2018] [Indexed: 01/28/2023] Open
Abstract
Pulmonary arterial hypertension (PAH) remains a disease with limited therapeutic options and dismal prognosis. Despite its etiologic heterogeneity, the underlying unifying pathophysiology is characterized by increased vascular tone and adverse remodeling of the pulmonary circulation. Myeloperoxidase (MPO), an enzyme abundantly expressed in neutrophils, has potent vasoconstrictive and profibrotic properties, thus qualifying as a potential contributor to this disease. Here, we sought to investigate whether MPO is causally linked to the pathophysiology of PAH. Investigation of 2 independent clinical cohorts revealed that MPO plasma levels were elevated in subjects with PAH and predicted adverse outcome. Experimental analyses showed that, upon hypoxia, right ventricular pressure was less increased in Mpo-/- than in WT mice. The hypoxia-induced activation of the Rho-kinase pathway, a critical subcellular signaling pathway yielding vasoconstriction and structural vascular remodeling, was blunted in Mpo-/- mice. Mice subjected to i.v. infusion of MPO revealed activation of Rho-kinase and increased right ventricular pressure, which was prevented by coinfusion of the Rho-kinase inhibitor Y-27632. In the Sugen5416/hypoxia rat model, PAH was attenuated by the MPO inhibitor AZM198. The current data demonstrate a tight mechanistic link between MPO, the activation of Rho-kinase, and adverse pulmonary vascular function, thus pointing toward a potentially novel avenue of treatment.
Collapse
Affiliation(s)
- Anna Klinke
- Heart Center, Department of Cardiology
- Center for Molecular Medicine Cologne CMMC, University of Cologne, Cologne, Germany
- International Clinical Research Center, Centre of Biomolecular and Cellular Engineering (CBCE), St. Anne’s University Hospital Brno, Brno, Czech Republic
| | - Eva Berghausen
- Heart Center, Department of Cardiology
- Center for Molecular Medicine Cologne CMMC, University of Cologne, Cologne, Germany
| | - Kai Friedrichs
- Heart Center, Department of Cardiology
- Center for Molecular Medicine Cologne CMMC, University of Cologne, Cologne, Germany
| | - Simon Molz
- University Heart Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Denise Lau
- University Heart Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Lisa Remane
- Heart Center, Department of Cardiology
- Center for Molecular Medicine Cologne CMMC, University of Cologne, Cologne, Germany
| | - Matthias Berlin
- Heart Center, Department of Cardiology
- Center for Molecular Medicine Cologne CMMC, University of Cologne, Cologne, Germany
| | - Charlotte Kaltwasser
- Heart Center, Department of Cardiology
- Center for Molecular Medicine Cologne CMMC, University of Cologne, Cologne, Germany
| | - Matti Adam
- Heart Center, Department of Cardiology
- Center for Molecular Medicine Cologne CMMC, University of Cologne, Cologne, Germany
| | - Dennis Mehrkens
- Heart Center, Department of Cardiology
- Center for Molecular Medicine Cologne CMMC, University of Cologne, Cologne, Germany
| | - Martin Mollenhauer
- Heart Center, Department of Cardiology
- Center for Molecular Medicine Cologne CMMC, University of Cologne, Cologne, Germany
| | - Kashish Manchanda
- Heart Center, Department of Cardiology
- Center for Molecular Medicine Cologne CMMC, University of Cologne, Cologne, Germany
| | - Thorben Ravekes
- Heart Center, Department of Cardiology
- Center for Molecular Medicine Cologne CMMC, University of Cologne, Cologne, Germany
| | | | - Metin Aytekin
- Pathobiology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA
| | - Raed A. Dweik
- Pulmonary and Critical Care Medicine, Respiratory Institute, and
| | - Jan K. Hennigs
- Cardiovascular Institute, Stanford University, School of Medicine, Stanford, California, USA
- Department of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Lukas Kubala
- International Clinical Research Center, Centre of Biomolecular and Cellular Engineering (CBCE), St. Anne’s University Hospital Brno, Brno, Czech Republic
- Institute of Biophysics, Czech Academy of Sciences, Brno, Czech Republic
| | - Erik Michaëlsson
- Bioscience Heart Failure, Cardiovascular, Renal and Metabolism, Innovative Medicines and Early Development (IMED) Biotech Unit, AstraZeneca, Gothenburg, Sweden
| | - Stephan Rosenkranz
- Heart Center, Department of Cardiology
- Center for Molecular Medicine Cologne CMMC, University of Cologne, Cologne, Germany
| | - Tanja K. Rudolph
- Heart Center, Department of Cardiology
- Center for Molecular Medicine Cologne CMMC, University of Cologne, Cologne, Germany
| | - Stanley L. Hazen
- Department of Cellular and Molecular Medicine, Cleveland Clinic, Cleveland, Ohio, USA
| | - Hans Klose
- Department of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Ralph T. Schermuly
- Universities of Giessen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research, Giessen, Germany
| | - Volker Rudolph
- Heart Center, Department of Cardiology
- Center for Molecular Medicine Cologne CMMC, University of Cologne, Cologne, Germany
| | - Stephan Baldus
- Heart Center, Department of Cardiology
- Center for Molecular Medicine Cologne CMMC, University of Cologne, Cologne, Germany
| |
Collapse
|
63
|
Wang W, Ren D, Wang C, Gong Y. Inhibition of myeloperoxidase might be a novel therapeutic target in the treatment of atherosclerosis. Int J Cardiol 2018; 256:33. [DOI: 10.1016/j.ijcard.2018.01.023] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/01/2018] [Accepted: 01/10/2018] [Indexed: 12/20/2022]
|
64
|
Vanhamme L, Zouaoui Boudjeltia K, Van Antwerpen P, Delporte C. The other myeloperoxidase: Emerging functions. Arch Biochem Biophys 2018; 649:1-14. [PMID: 29614255 DOI: 10.1016/j.abb.2018.03.037] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2017] [Revised: 03/07/2018] [Accepted: 03/30/2018] [Indexed: 12/20/2022]
Abstract
Myeloperoxidase (MPO) is a member of the mammalian peroxidase family. It is mainly expressed in neutrophils, monocytes and macrophages. As a catalyzer of reactive oxidative species and radical species formation, it contributes to neutrophil bactericidal activity. Nevertheless MPO invalidation does not seem to have major health consequences in affected individuals. This suggests that MPO might have alternative functions supporting its conservation during evolution. We will review the available data supporting these non-canonical functions in terms of tissue specific expression, function and enzymatic activity. Thus, we discuss its cell type specific expression. We review in between others its roles in angiogenesis, endothelial (dys-) function, immune reaction, and inflammation. We summarize its pathological actions in clinical conditions such as cardiovascular disease and cancer.
Collapse
Affiliation(s)
- Luc Vanhamme
- Laboratory of Molecular Biology of Inflammation, IBMM, Faculty of Sciences, Université Libre de Bruxelles, Gosselies, Belgium; Laboratory of Experimental Medicine (ULB 222 Unit), CHU de Charleroi, A. Vésale Hospital, Université Libre de Bruxelles, Montigny-le-Tilleul, Belgium.
| | - Karim Zouaoui Boudjeltia
- Laboratory of Experimental Medicine (ULB 222 Unit), CHU de Charleroi, A. Vésale Hospital, Université Libre de Bruxelles, Montigny-le-Tilleul, Belgium
| | - Pierre Van Antwerpen
- Pharmacognosy, Bioanalysis and Drug Discovery Unit, RD3, and Analytical Platform of the Faculty of Pharmacy, Faculty of Pharmacy, Université Libre de Bruxelles, Brussels, Belgium
| | - Cédric Delporte
- Pharmacognosy, Bioanalysis and Drug Discovery Unit, RD3, and Analytical Platform of the Faculty of Pharmacy, Faculty of Pharmacy, Université Libre de Bruxelles, Brussels, Belgium.
| |
Collapse
|
65
|
Ock SA, Oh KB, Hwang S, Yun IJ, Ahn C, Chee HK, Kim H, Ullah I, Im GS, Park EW. Immune molecular profiling of whole blood drawn from a non-human primate cardiac xenograft model treated with anti-CD154 monoclonal antibodies. Xenotransplantation 2018; 25:e12392. [PMID: 29582477 DOI: 10.1111/xen.12392] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/02/2017] [Revised: 01/17/2018] [Accepted: 02/22/2018] [Indexed: 12/17/2022]
Abstract
Most studies of xenografts have been carried out with complex immunosuppressive regimens to prevent immune rejection; however, such treatments may be fatal owing to unknown causes. Here, we performed immune molecular profiling following anti-CD154 monoclonal antibody (mAb) treatment in heterotopic abdominal cardiac xenografts from α-1,3-galactosyltransferase-knockout pigs into cynomolgus monkeys to elucidate the mechanisms mediating the undesirable fatal side effects of immunosuppressive agents. Blood samples were collected from healthy monkeys as control and then at 2 days after xenograft transplantation and just before humane euthanasia; 94 genes related to the immune system were analyzed. The basic immunosuppressive regimen included cobra venom factor, anti-thymocyte globulin, and rituximab, with and without anti-CD154 mAbs. The maintenance therapy was followed with tacrolimus, MMF, and methylprednisolone. The number of upregulated genes was initially decreased on Day 2 (-/+ anti-CD154 mAb, 22/13) and then increased before euthanasia in recipients treated with anti-CD154 mAbs (-/+ anti-CD154 mAb, 30/37). The number of downregulated genes was not affected by anti-CD154 mAb treatment. Additionally, the number of upregulated genes increased over time for both groups. Interestingly, treatment with anti-CD154 mAbs upregulated coagulation inducers (CCL2/IL6) before euthanasia. In conclusion, immunosuppressive regimens used for cardiac xenografting affected upregulation of 6 inflammation genes (CXCL10, MPO, MYD88, NLRP3, TNFα, and TLR1) and downregulation of 8 genes (CCR4, CCR6, CD40, CXCR3, FOXP3, GATA3, STAT4, and TBX21).
Collapse
Affiliation(s)
- Sun A Ock
- Animal Biotechnology Division, National Institute of Animal Science, Rural Development Administration, Wanju-gun, Jeollabuk-do, Korea
| | - Keon Bong Oh
- Animal Biotechnology Division, National Institute of Animal Science, Rural Development Administration, Wanju-gun, Jeollabuk-do, Korea
| | - Seongsoo Hwang
- Animal Biotechnology Division, National Institute of Animal Science, Rural Development Administration, Wanju-gun, Jeollabuk-do, Korea
| | - Ik Jin Yun
- Department of Surgery, Konkuk University School of Medicine, Seoul, Korea
| | - Curie Ahn
- Division of Nephrology, Seoul National University College of Medicine, Seoul, Korea.,Designed Animal & Transplantation Research institute, Institute of Green BioScience & Technology, Seoul National University, Pyeongchang, Gangwon-do, Korea
| | - Hyun Ken Chee
- Department of Cardiothoracic Surgery, Konkuk University School of Medicine, Seoul, Korea
| | - Hwajung Kim
- Division of Nephrology, Seoul National University College of Medicine, Seoul, Korea
| | - Imran Ullah
- Animal Biotechnology Division, National Institute of Animal Science, Rural Development Administration, Wanju-gun, Jeollabuk-do, Korea
| | - Gi-Sun Im
- Animal Biotechnology Division, National Institute of Animal Science, Rural Development Administration, Wanju-gun, Jeollabuk-do, Korea
| | - Eung Woo Park
- Animal Biotechnology Division, National Institute of Animal Science, Rural Development Administration, Wanju-gun, Jeollabuk-do, Korea
| |
Collapse
|
66
|
Kemer Doğan ES, Kırzıoğlu FY, Doğan B, Fentoğlu Ö, Kale B. The effect of menopause on the relationship between hyperlipidemia and periodontal disease via salivary 8-hydroxy-2'-deoxyguanosine and myeloperoxidase levels. Acta Odontol Scand 2018; 76:92-97. [PMID: 28984174 DOI: 10.1080/00016357.2017.1386798] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
OBJECTIVE Impairment of the lipid metabolism could affect the periodontal disease; increased oxidative stress may have a role in this relationship. The aim of the present study was to evaluate the role of menopause in the relationship between hyperlipidemia and periodontal disease via oxidative stress markers in saliva. MATERIALS AND METHODS Sixty-seven women were enrolled in the study and divided into four groups as systemically healthy and premenopause (C) (n = 18), hyperlipidemia and premenopause (H) (n = 16), systemically healthy and postmenopause (M) (n = 17), and hyperlipidemia and postmenopause (MH) (n = 16). Sociodemographics, periodontal and metabolic parameters, and saliva oxidative markers (myeloperoxidase [MPO] and 8-hydroxy-2'-deoxyguanosine [8-OHdG]) were evaluated. RESULTS Menopause and/or hyperlipidemia were associated with an increase in all evaluated periodontal parameters. Saliva 8-OHdG and MPO levels were higher in menopausal groups (M and MH). Multivariate linear regression analyses revealed that hyperlipidemia was related to an increase in periodontal parameters. Salivary oxidative stress markers and periodontal parameters were also positively associated with menopause and hyperlipidemia. CONCLUSION Saliva 8-OHdG and MPO levels may indicate that the relationship between periodontal disease and hyperlipidemia is aggravated by menopause.
Collapse
Affiliation(s)
- Esra Sinem Kemer Doğan
- Department of Periodontology, Faculty of Dentistry, Mustafa Kemal University, Hatay, Turkey
| | - Fatma Yeşim Kırzıoğlu
- Department of Periodontology, Faculty of Dentistry, Süleyman Demirel University, Isparta, Turkey
| | - Burak Doğan
- Department of Periodontology, Faculty of Dentistry, Mustafa Kemal University, Hatay, Turkey
| | - Özlem Fentoğlu
- Department of Periodontology, Faculty of Dentistry, Süleyman Demirel University, Isparta, Turkey
| | - Banu Kale
- Endocrinologist, Private Practice, Isparta, Turkey
| |
Collapse
|
67
|
Near-infrared heat lamp therapeutic effect on paraoxonase 1 and myeloperoxidase as potential biomarkers of redox state changes induced by γ-irradiation in albino rats. JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B-BIOLOGY 2018; 179:105-112. [DOI: 10.1016/j.jphotobiol.2018.01.009] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/10/2017] [Revised: 01/09/2018] [Accepted: 01/12/2018] [Indexed: 11/21/2022]
|
68
|
Portulaca Extract Attenuates Development of Dextran Sulfate Sodium Induced Colitis in Mice through Activation of PPAR γ. PPAR Res 2018; 2018:6079101. [PMID: 29483924 PMCID: PMC5816873 DOI: 10.1155/2018/6079101] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2017] [Revised: 09/14/2017] [Accepted: 11/28/2017] [Indexed: 12/22/2022] Open
Abstract
Portulaca oleracea L. is a traditional Chinese medicine, which has been used as adjuvant therapy for inflammatory bowel disease (IBD). However, the mechanism of its activity in IBD still remains unclear. Since previous studies have documented the anti-inflammatory effect of peroxisome proliferator activated receptors-γ (PPAR-γ), Portulaca regulation of PPAR-γ in inflammation was examined in current study. Ulcerative colitis (UC) was generated by 5% dextran sulfate sodium (DSS) in mice and four groups were established as normal control, DSS alone, DSS plus mesalamine, and DSS plus Portulaca. Severity of UC was evaluated by body weight, stool blood form, and length of colorectum. Inflammation was examined by determination of inflammatory cytokines (TNF-a, IL-6, and IL-1a). Portulaca extract was able to attenuate development of UC in DSS model similar to the treatment of mesalazine. Moreover, Portulaca extract inhibited proinflammatory cytokines release and reduced the level of DSS-induced NF-κB phosphorylation. Furthermore, Portulaca extract restored PPAR-γ level, which was reduced by DSS. In addition, Portulaca extract protected DSS induced apoptosis in mice. In conclusion, Portulaca extract can alleviate colitis in mice through regulation of inflammatory reaction, apoptosis, and PPAR-γ level; therefore, Portulaca extract can be a potential candidate for the treatment of IBD.
Collapse
|
69
|
Role of Quzhou Fructus Aurantii Extract in Preventing and Treating Acute Lung Injury and Inflammation. Sci Rep 2018; 8:1698. [PMID: 29374248 PMCID: PMC5785969 DOI: 10.1038/s41598-018-20083-z] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2017] [Accepted: 01/10/2018] [Indexed: 01/03/2023] Open
Abstract
Quzhou Fructus Aurantii (QFA) is an authentic herb of local varieties in Zhejiang, China, which is usually used to treat gastrointestinal illnesses, but its effects on respiratory inflammation have not been reported yet. In our study, the anti-inflammatory activity of QFA extract (QFAE) was evaluated on copper sulfate pentahydrate (CuSO4·5H2O)-induced transgenic neutrophil fluorescent zebrafish model. QFAE showed a significant effect of anti-inflammation in CuSO4·5H2O-induced zebrafish by reducing the neutrophil number in the inflammatory site. We investigated the anti-inflammatory activity of QFAE on lipopolysaccharide (LPS)-induced acute lung injury (ALI) mice models and RAW 264.7 cells. QFAE had an anti-inflammatory effect on reducing total cells, neutrophils, and macrophages in BALF and attenuated alveolus collapse, neutrophils infiltration, lung W/D ratio, myeloperoxidase (MPO) protein expression and other pulmonary histological changes in lung tissues, as well as hematological changes. Levels of pro-inflammatory cytokines, including TNF, IL-6, IFN-γ, MCP-1, and IL-12p70, were decreased, whereas anti-inflammatory cytokine IL-10 was increased after treatment with QFAE both in vivo and in vitro. In summary, our results suggested that QFAE had apparent anti-inflammatory effects on CuSO4·5H2O-induced zebrafish, LPS-induced ALI mice, and RAW 264.7 cells. Furthermore, QFAE may be a therapeutic drug to treat ALI/ARDS and other respiratory inflammations.
Collapse
|
70
|
Witkowski A, Chan GKL, Boatz JC, Li NJ, Inoue AP, Wong JC, van der Wel PCA, Cavigiolio G. Methionine oxidized apolipoprotein A-I at the crossroads of HDL biogenesis and amyloid formation. FASEB J 2018; 32:3149-3165. [PMID: 29401604 DOI: 10.1096/fj.201701127r] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
Apolipoprotein A-I (apoA-I) shares with other exchangeable apolipoproteins a high level of structural plasticity. In the lipid-free state, the apolipoprotein amphipathic α-helices interact intra- and intermolecularly, providing structural stabilization by self-association. We have reported that lipid-free apoA-I becomes amyloidogenic upon physiologically relevant (myeloperoxidase-mediated) Met oxidation. In this study, we established that Met oxidation promotes amyloidogenesis by reducing the stability of apoA-I monomers and irreversibly disrupting self-association. The oxidized apoA-I monomers also exhibited increased cellular cholesterol release capacity and stronger association with macrophages, compared to nonoxidized apoA-I. Of physiologic relevance, preformed oxidized apoA-I amyloid fibrils induced amyloid formation in nonoxidized apoA-I. This process was enhanced when self-association of nonoxidized apoA-I was disrupted by thermal treatment. Solid state NMR analysis revealed that aggregates formed by seeded nonoxidized apoA-I were structurally similar to those formed by the oxidized protein, featuring a β-structure-rich amyloid fold alongside α-helices retained from the native state. In atherosclerotic lesions, the conditions that promote apoA-I amyloid formation are readily available: myeloperoxidase, active oxygen species, low pH, and high concentration of lipid-free apoA-I. Our results suggest that even partial Met oxidation of apoA-I can nucleate amyloidogenesis, thus sequestering and inactivating otherwise antiatherogenic and HDL-forming apoA-I.-Witkowski, A., Chan, G. K. L., Boatz, J. C., Li, N. J., Inoue, A. P., Wong, J. C., van der Wel, P. C. A., Cavigiolio, G. Methionine oxidized apolipoprotein A-I at the crossroads of HDL biogenesis and amyloid formation.
Collapse
Affiliation(s)
- Andrzej Witkowski
- Children's Hospital Oakland Research Institute (CHORI), Oakland, California, USA
| | - Gary K L Chan
- Children's Hospital Oakland Research Institute (CHORI), Oakland, California, USA
| | - Jennifer C Boatz
- Department of Structural Biology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
| | - Nancy J Li
- Children's Hospital Oakland Research Institute (CHORI), Oakland, California, USA
| | - Ayuka P Inoue
- Children's Hospital Oakland Research Institute (CHORI), Oakland, California, USA
| | - Jaclyn C Wong
- Children's Hospital Oakland Research Institute (CHORI), Oakland, California, USA
| | | | - Giorgio Cavigiolio
- Children's Hospital Oakland Research Institute (CHORI), Oakland, California, USA
| |
Collapse
|
71
|
Rossetto Burgos RC, Ramautar R, Van Wijk EP, Hankemeier T, Der Greef JV, Mashaghi A. Pharmacological targeting of ROS reaction network in myeloid leukemia cells monitored by ultra-weak photon emission. Oncotarget 2018; 9:2028-2034. [PMID: 29416750 PMCID: PMC5788618 DOI: 10.18632/oncotarget.23175] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2016] [Accepted: 11/20/2017] [Indexed: 12/28/2022] Open
Abstract
Acute myeloid leukemia (AML) is a blood cancer that is caused by a disorder of the process that normally generates neutrophils. Function and dysfunction of neutrophils are key to physiologic defense against pathogens as well as pathologies including autoimmunity and cancer. A major mechanism through which neutrophils contribute to health and disease is oxidative burst, which involves rapid release of reactive oxygen species (ROS) generated by a chemical reaction network catalyzed by enzymes including NADPH oxidase and myeloperoxidase (MPO). Due to the involvement of neutrophil-derived reactive oxygen species in many diseases and importance of NADPH oxidase and MPO-mediated reactions in progression and treatment of myeloid leukemia, monitoring this process and modulating it by pharmacological interventions is of great interest. In this work, we have evaluated the potential of a label-free method using ultra-weak photon emission (UPE) to monitor ROS production in neutrophil-like HL60 myeloid leukemia cells. Suppression of ROS was achieved by several drug candidates that target different parts of the reaction pathway. Our results show that UPE can report on ROS production as well as suppression by pharmacological inhibitors. We find that UPE is primarily generated by MPO catalyzed reaction and thus will be affected when an upstream reaction is pharmacologically modulated.
Collapse
Affiliation(s)
- Rosilene Cristina Rossetto Burgos
- Leiden Academic Centre for Drug Research, Faculty of Mathematics and Natural Sciences, Leiden University, 2300 RA Leiden, The Netherlands
- Sino-Dutch Centre for Preventive and Personalized Medicine/Centre for Photonics of Living Systems, Leiden University, 2300 RA Leiden, The Netherlands
| | - Rawi Ramautar
- Leiden Academic Centre for Drug Research, Faculty of Mathematics and Natural Sciences, Leiden University, 2300 RA Leiden, The Netherlands
| | - Eduard P.A. Van Wijk
- Sino-Dutch Centre for Preventive and Personalized Medicine/Centre for Photonics of Living Systems, Leiden University, 2300 RA Leiden, The Netherlands
| | - Thomas Hankemeier
- Leiden Academic Centre for Drug Research, Faculty of Mathematics and Natural Sciences, Leiden University, 2300 RA Leiden, The Netherlands
| | - Jan Van Der Greef
- Leiden Academic Centre for Drug Research, Faculty of Mathematics and Natural Sciences, Leiden University, 2300 RA Leiden, The Netherlands
- Sino-Dutch Centre for Preventive and Personalized Medicine/Centre for Photonics of Living Systems, Leiden University, 2300 RA Leiden, The Netherlands
| | - Alireza Mashaghi
- Leiden Academic Centre for Drug Research, Faculty of Mathematics and Natural Sciences, Leiden University, 2300 RA Leiden, The Netherlands
| |
Collapse
|
72
|
Akentieva NP, Sanina NA, Gizatullin AR, Shmatko NY, Goryachev NS, Shkondina NI, Prikhodchenko TR, Aldoshin SM. The inhibitory effect of dinitrosyl iron complexes (NO donors) on myeloperoxidase activity. DOKL BIOCHEM BIOPHYS 2018; 477:389-393. [DOI: 10.1134/s1607672917060126] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2017] [Indexed: 11/23/2022]
|
73
|
Talluri MR, Killari KN, Viswanadha Murthy Manepalli N, Konduri P, Bandaru KK. Protective effect of Canna indica on cerebral ischemia-reperfusion injury in rats. ACTA ACUST UNITED AC 2017. [DOI: 10.1016/j.anres.2018.03.007] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
74
|
|
75
|
Kim HW, Blomkalns AL, Ogbi M, Thomas M, Gavrila D, Neltner BS, Cassis LA, Thompson RW, Weiss RM, Lindower PD, Blanco VM, McCormick ML, Daugherty A, Fu X, Hazen SL, Stansfield BK, Huo Y, Fulton DJ, Chatterjee T, Weintraub NL. Role of myeloperoxidase in abdominal aortic aneurysm formation: mitigation by taurine. Am J Physiol Heart Circ Physiol 2017; 313:H1168-H1179. [PMID: 28971841 PMCID: PMC5814655 DOI: 10.1152/ajpheart.00296.2017] [Citation(s) in RCA: 42] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/31/2017] [Revised: 08/03/2017] [Accepted: 08/28/2017] [Indexed: 01/16/2023]
Abstract
Oxidative stress plays a fundamental role in abdominal aortic aneurysm (AAA) formation. Activated polymorphonuclear leukocytes (or neutrophils) are associated with AAA and express myeloperoxidase (MPO), which promotes inflammation, matrix degradation, and other pathological features of AAA, including enhanced oxidative stress through generation of reactive oxygen species. Both plasma and aortic MPO levels are elevated in patients with AAA, but the role of MPO in AAA pathogenesis has, heretofore, never been investigated. Here, we show that MPO gene deletion attenuates AAA formation in two animal models: ANG II infusion in apolipoprotein E-deficient mice and elastase perfusion in C57BL/6 mice. Oral administration of taurine [1% or 4% (wt/vol) in drinking water], an amino acid known to react rapidly with MPO-generated oxidants like hypochlorous acid, also prevented AAA formation in the ANG II and elastase models as well as the CaCl2 application model of AAA formation while reducing aortic peroxidase activity and aortic protein-bound dityrosine levels, an oxidative cross link formed by MPO. Both MPO gene deletion and taurine supplementation blunted aortic macrophage accumulation, elastin fragmentation, and matrix metalloproteinase activation, key features of AAA pathogenesis. Moreover, MPO gene deletion and taurine administration significantly attenuated the induction of serum amyloid A, which promotes ANG II-induced AAAs. These data implicate MPO in AAA pathogenesis and suggest that studies exploring whether taurine can serve as a potential therapeutic for the prevention or treatment of AAA in patients merit consideration.NEW & NOTEWORTHY Neutrophils are abundant in abdominal aortic aneurysm (AAA), and myeloperoxidase (MPO), prominently expressed in neutrophils, is associated with AAA in humans. This study demonstrates that MPO gene deletion or supplementation with the natural product taurine, which can scavenge MPO-generated oxidants, can prevent AAA formation, suggesting an attractive potential therapeutic strategy for AAA.
Collapse
MESH Headings
- Angiotensin II
- Animals
- Antioxidants/pharmacology
- Aorta, Abdominal/drug effects
- Aorta, Abdominal/enzymology
- Aorta, Abdominal/pathology
- Aortic Aneurysm, Abdominal/chemically induced
- Aortic Aneurysm, Abdominal/enzymology
- Aortic Aneurysm, Abdominal/genetics
- Aortic Aneurysm, Abdominal/prevention & control
- Calcium Chloride
- Disease Models, Animal
- Gene Deletion
- Male
- Mice, Inbred C57BL
- Mice, Knockout, ApoE
- Neutrophils/drug effects
- Neutrophils/enzymology
- Oxidative Stress/drug effects
- Pancreatic Elastase
- Peroxidase/deficiency
- Peroxidase/genetics
- Peroxidase/metabolism
- Reactive Oxygen Species/metabolism
- Serum Amyloid A Protein/metabolism
- Taurine/pharmacology
Collapse
Affiliation(s)
- Ha Won Kim
- Division of Cardiology, Department of Medicine, Medical College of Georgia at Augusta University, Augusta, Georgia
| | - Andra L Blomkalns
- Department of Emergency Medicine, Medical College of Georgia at Augusta University, Augusta, Georgia
| | - Mourad Ogbi
- Division of Cardiology, Department of Medicine, Medical College of Georgia at Augusta University, Augusta, Georgia
| | - Manesh Thomas
- Division of Cardiovascular Medicine, University of Iowa, Iowa City, Iowa
| | - Daniel Gavrila
- Division of Cardiovascular Medicine, University of Iowa, Iowa City, Iowa
| | - Bonnie S Neltner
- Division of Cardiovascular Diseases, Department of Internal Medicine, University of Cincinnati, Cincinnati, Ohio
| | - Lisa A Cassis
- Department of Pharmacology and Nutritional Sciences, University of Kentucky, Lexington, Kentucky
| | - Robert W Thompson
- Department of Surgery, Washington University School of Medicine, St. Louis, Missouri
| | - Robert M Weiss
- Division of Cardiovascular Medicine, University of Iowa, Iowa City, Iowa
| | - Paul D Lindower
- Division of Cardiovascular Medicine, University of Iowa, Iowa City, Iowa
| | - Victor M Blanco
- Division of Cardiovascular Diseases, Department of Internal Medicine, University of Cincinnati, Cincinnati, Ohio
| | | | - Alan Daugherty
- Departmentof Physiology and Saha Cardiovascular Research Center, University of Kentucky, Lexington, Kentucky; and
| | - Xiaoming Fu
- Department of Cellular and Molecular Medicine, Cleveland Clinic, Cleveland, Ohio
| | - Stanley L Hazen
- Department of Cellular and Molecular Medicine, Cleveland Clinic, Cleveland, Ohio
| | - Brian K Stansfield
- Department of Pediatrics, Medical College of Georgia at Augusta University, Augusta, Georgia
| | - Yuqing Huo
- Department of Cellular Biology and Anatomy, Medical College of Georgia at Augusta University, Augusta, Georgia
| | - David J Fulton
- Department of Pharmacology and Toxicology, Vascular Biology Center, Medical College of Georgia at Augusta University, Augusta, Georgia
| | - Tapan Chatterjee
- Division of Cardiology, Department of Medicine, Medical College of Georgia at Augusta University, Augusta, Georgia
| | - Neal L Weintraub
- Division of Cardiology, Department of Medicine, Medical College of Georgia at Augusta University, Augusta, Georgia;
| |
Collapse
|
76
|
Phuah CL, Dave T, Malik R, Raffeld MR, Ayres AM, Goldstein JN, Viswanathan A, Greenberg SM, Jagiella JM, Hansen BM, Norrving B, Jimenez-Conde J, Roquer J, Pichler A, Enzinger C, Montaner J, Fernandez-Cadenas I, Lindgren A, Slowik A, Schmidt R, Biffi A, Rost N, Langefeld CD, Markus HS, Mitchell BD, Worrall BB, Kittner SJ, Woo D, Dichgans M, Rosand J, Anderson CD. Genetic variants influencing elevated myeloperoxidase levels increase risk of stroke. Brain 2017; 140:2663-2672. [PMID: 28969386 DOI: 10.1093/brain/awx220] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2017] [Accepted: 07/08/2017] [Indexed: 12/13/2022] Open
Abstract
Primary intracerebral haemorrhage and lacunar ischaemic stroke are acute manifestations of progressive cerebral microvascular disease. Current paradigms suggest atherosclerosis is a chronic, dynamic, inflammatory condition precipitated in response to endothelial injury from various environmental challenges. Myeloperoxidase plays a central role in initiation and progression of vascular inflammation, but prior studies linking myeloperoxidase with stroke risk have been inconclusive. We hypothesized that genetic determinants of myeloperoxidase levels influence the development of vascular instability, leading to increased primary intracerebral haemorrhage and lacunar stroke risk. We used a discovery cohort of 1409 primary intracerebral haemorrhage cases and 1624 controls from three studies, an extension cohort of 12 577 ischaemic stroke cases and 25 643 controls from NINDS-SiGN, and a validation cohort of 10 307 ischaemic stroke cases and 29 326 controls from METASTROKE Consortium with genome-wide genotyping to test this hypothesis. A genetic risk score reflecting elevated myeloperoxidase levels was constructed from 15 common single nucleotide polymorphisms identified from prior genome-wide studies of circulating myeloperoxidase levels (P < 5 × 10-6). This genetic risk score was used as the independent variable in multivariable regression models for association with primary intracerebral haemorrhage and ischaemic stroke subtypes. We used fixed effects meta-analyses to pool estimates across studies. We also used Cox regression models in a prospective cohort of 174 primary intracerebral haemorrhage survivors for association with intracerebral haemorrhage recurrence. We present effects of myeloperoxidase elevating single nucleotide polymorphisms on stroke risk per risk allele, corresponding to a one allele increase in the myeloperoxidase increasing genetic risk score. Genetic determinants of elevated circulating myeloperoxidase levels were associated with both primary intracerebral haemorrhage risk (odds ratio, 1.07, P = 0.04) and recurrent intracerebral haemorrhage risk (hazards ratio, 1.45, P = 0.006). In analysis of ischaemic stroke subtypes, the myeloperoxidase increasing genetic risk score was strongly associated with lacunar subtype only (odds ratio, 1.05, P = 0.0012). These results, demonstrating that common genetic variants that increase myeloperoxidase levels increase risk of primary intracerebral haemorrhage and lacunar stroke, directly implicate the myeloperoxidase pathway in the pathogenesis of cerebral small vessel disease. Because genetic variants are not influenced by environmental exposures, these results provide new support for a causal rather than bystander role for myeloperoxidase in the progression of cerebrovascular disease. Furthermore, these results support a rationale for chronic inflammation as a potential modifiable stroke risk mechanism, and suggest that immune-targeted therapies could be useful for treatment and prevention of cerebrovascular disease.
Collapse
Affiliation(s)
- Chia-Ling Phuah
- Center for Human Genetic Research, Massachusetts General Hospital (MGH), Boston, MA, USA.,Division of Neurocritical Care and Emergency Neurology, Department of Neurology, MGH, Boston, MA, USA
| | - Tushar Dave
- Division of Endocrinology, Diabetes and Nutrition, Department of Medicine, University of Maryland School of Medicine, Baltimore, USA
| | - Rainer Malik
- Institute for Stroke and Dementia Research, Klinikum der Universität München, Ludwig-Maximilians-Universität München, Munich, Germany
| | - Miriam R Raffeld
- Center for Human Genetic Research, Massachusetts General Hospital (MGH), Boston, MA, USA
| | - Alison M Ayres
- Center for Human Genetic Research, Massachusetts General Hospital (MGH), Boston, MA, USA.,J. Philip Kistler Stroke Research Center, Department of Neurology, MGH, Boston, MA, USA
| | | | - Anand Viswanathan
- Program in Medical and Population Genetics, Broad Institute, Cambridge, MA, USA
| | - Steven M Greenberg
- J. Philip Kistler Stroke Research Center, Department of Neurology, MGH, Boston, MA, USA
| | - Jeremiasz M Jagiella
- Department of Neurology, Jagiellonian University Medical College, Krakow, Poland
| | - Björn M Hansen
- Department of Clinical Sciences Lund, Neurology, Lund University, Lund, Sweden.,Department of Neurology and Rehabilitation Medicine, Neurology, Skåne University Hospital, Lund, Sweden
| | - Bo Norrving
- Department of Clinical Sciences Lund, Neurology, Lund University, Lund, Sweden.,Department of Neurology and Rehabilitation Medicine, Neurology, Skåne University Hospital, Lund, Sweden
| | - Jordi Jimenez-Conde
- Neurovascular Research Unit, Department of Neurology, Institut Municipal d'Investigacio´ Medica-Hospital del Mar, Universitat Autonoma de Barcelona, Barcelona, Spain.,Program in Inflammation and Cardiovascular Disorders, Institut Municipal d'Investigacio´ Medica-Hospital del Mar, Universitat Autonoma de Barcelona, Barcelona, Spain
| | - Jaume Roquer
- Neurovascular Research Unit, Department of Neurology, Institut Municipal d'Investigacio´ Medica-Hospital del Mar, Universitat Autonoma de Barcelona, Barcelona, Spain.,Program in Inflammation and Cardiovascular Disorders, Institut Municipal d'Investigacio´ Medica-Hospital del Mar, Universitat Autonoma de Barcelona, Barcelona, Spain
| | | | - Christian Enzinger
- Department of Neurology, Medical University of Graz, Austria.,Division of Neuroradiology, Department of Radiology, Medical University of Graz, Austria
| | - Joan Montaner
- Neurovascular Research Laboratory and Neurovascular Unit, Institut de Recerca, Hospital Vall d'Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain
| | - Israel Fernandez-Cadenas
- Neurovascular Research Laboratory and Neurovascular Unit, Institut de Recerca, Hospital Vall d'Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain.,Stroke Pharmacogenomics and Genetics, Fundació Docència i Recerca Mutua Terrassa, Mutua de Terrassa Hospital, Terrassa, Spain
| | - Arne Lindgren
- Department of Clinical Sciences Lund, Neurology, Lund University, Lund, Sweden.,Department of Neurology and Rehabilitation Medicine, Neurology, Skåne University Hospital, Lund, Sweden
| | - Agnieszka Slowik
- Department of Neurology, Jagiellonian University Medical College, Krakow, Poland
| | | | - Alessandro Biffi
- Center for Human Genetic Research, Massachusetts General Hospital (MGH), Boston, MA, USA.,J. Philip Kistler Stroke Research Center, Department of Neurology, MGH, Boston, MA, USA.,Division of Behavioral Neurology, Department of Neurology, MGH, Boston, MA, USA.,Division of Neuropsychiatry, Department of Psychiatry, MGH, Boston, MA, USA
| | - Natalia Rost
- J. Philip Kistler Stroke Research Center, Department of Neurology, MGH, Boston, MA, USA
| | - Carl D Langefeld
- Center for Public Health Genomics, Wake Forest School of Medicine, Winston-Salem, NC, USA
| | - Hugh S Markus
- Department of Clinical Neurosciences, University of Cambridge, UK
| | - Braxton D Mitchell
- Geriatrics Research and Education Clinical Center, Baltimore Veterans Administration Medical Center, Baltimore, MD, USA
| | - Brad B Worrall
- Department of Neurology, University of Virginia, Charlottesville, VA, USA.,Department of Public Health Science, University of Virginia, Charlottesville, VA, USA
| | - Steven J Kittner
- Department of Neurology, University of Maryland School of Medicine, Baltimore, MD, USA.,Department of Neurology, Veterans Affairs Medical Center, Baltimore, MD, USA
| | - Daniel Woo
- University of Cincinnati College of Medicine, Cincinnati, OH, USA
| | - Martin Dichgans
- Institute for Stroke and Dementia Research, Klinikum der Universität München, Ludwig-Maximilians-Universität München, Munich, Germany.,German Center for Neurodegenerative Diseases (DZNE) and Munich Cluster for Systems Neurology (SyNergy), Germany
| | - Jonathan Rosand
- Center for Human Genetic Research, Massachusetts General Hospital (MGH), Boston, MA, USA.,Division of Neurocritical Care and Emergency Neurology, Department of Neurology, MGH, Boston, MA, USA.,J. Philip Kistler Stroke Research Center, Department of Neurology, MGH, Boston, MA, USA
| | - Christopher D Anderson
- Center for Human Genetic Research, Massachusetts General Hospital (MGH), Boston, MA, USA.,Division of Neurocritical Care and Emergency Neurology, Department of Neurology, MGH, Boston, MA, USA.,Program in Medical and Population Genetics, Broad Institute, Cambridge, MA, USA.,J. Philip Kistler Stroke Research Center, Department of Neurology, MGH, Boston, MA, USA
| | | | | | | |
Collapse
|
77
|
Polosa R, Russell C, Nitzkin J, Farsalinos KE. A critique of the US Surgeon General's conclusions regarding e-cigarette use among youth and young adults in the United States of America. Harm Reduct J 2017; 14:61. [PMID: 28874159 PMCID: PMC5586058 DOI: 10.1186/s12954-017-0187-5] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2017] [Accepted: 08/29/2017] [Indexed: 02/06/2023] Open
Abstract
BACKGROUND In December 2016, the Surgeon General published a report that concluded e-cigarette use among youth and young adults is becoming a major public health concern in the United States of America. METHODS Re-analysis of key data sources on nicotine toxicity and prevalence of youth use of e-cigarettes cited in the Surgeon General report as the basis for its conclusions. RESULTS Multiple years of nationally representative surveys indicate the majority of e-cigarette use among US youth is either infrequent or experimental, and negligible among never-smoking youth. The majority of the very small proportion of US youth who use e-cigarettes on a regular basis, consume nicotine-free products. The sharpest declines in US youth smoking rates have occurred as e-cigarettes have become increasingly available. Most of the evidence presented in the Surgeon General's discussion of nicotine harm is not applicable to e-cigarette use, because it relies almost exclusively on exposure to nicotine in the cigarette smoke and not to nicotine present in e-cigarette aerosol emissions. Moreover, the referenced literature describes effects in adults, not youth, and in animal models that have little relevance to real-world e-cigarette use by youth. The Surgeon General's report is an excellent reference document for the adverse outcomes due to nicotine in combination with several other toxicants present in tobacco smoke, but fails to address the risks of nicotine decoupled from tobacco smoke constituents. The report exaggerates the toxicity of propylene glycol (PG) and vegetable glycerin (VG) by focusing on experimental conditions that do not reflect use in the real-world and provides little discussion of emerging evidence that e-cigarettes may significantly reduce harm to smokers who have completely switched. CONCLUSIONS The U.S. Surgeon General's claim that e-cigarette use among U.S. youth and young adults is an emerging public health concern does not appear to be supported by the best available evidence on the health risks of nicotine use and population survey data on prevalence of frequent e-cigarette use. Nonetheless, patterns of e-cigarettes use in youth must be constantly monitored for early detection of significant changes. The next US Surgeon General should consider the possibility that future generations of young Americans will be less likely to start smoking tobacco because of, not in spite of, the availability of e-cigarettes.
Collapse
Affiliation(s)
- Riccardo Polosa
- Centro Prevenzione e Cura del Tabagismo, Azienda Ospedaliero Universitaria "Policlinico-V. Emanuele", Catania, Italy.
- Dipartimento di Medicina Clinica e Sperimentale, Università di Catania, Catania, Italy.
- UOC di Medicina Interna e d'Urgenza, Azienda Ospedaliero Universitaria "Policlinico-V. Emanuele", Catania, Italy.
| | | | | | - Konstantinos E Farsalinos
- Department of Cardiology, Onassis Cardiac Surgery Center, Sygrou 356, 17674, Kallithea, Greece
- Department of Pharmacy, University of Patras, 17674, Rio, Greece
| |
Collapse
|
78
|
Mollenhauer M, Friedrichs K, Lange M, Gesenberg J, Remane L, Kerkenpaß C, Krause J, Schneider J, Ravekes T, Maass M, Halbach M, Peinkofer G, Saric T, Mehrkens D, Adam M, Deuschl FG, Lau D, Geertz B, Manchanda K, Eschenhagen T, Kubala L, Rudolph TK, Wu Y, Tang WHW, Hazen SL, Baldus S, Klinke A, Rudolph V. Myeloperoxidase Mediates Postischemic Arrhythmogenic Ventricular Remodeling. Circ Res 2017; 121:56-70. [PMID: 28404615 PMCID: PMC5482785 DOI: 10.1161/circresaha.117.310870] [Citation(s) in RCA: 58] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/21/2017] [Revised: 03/20/2017] [Accepted: 04/11/2017] [Indexed: 01/09/2023]
Abstract
RATIONALE Ventricular arrhythmias remain the leading cause of death in patients suffering myocardial ischemia. Myeloperoxidase, a heme enzyme released by polymorphonuclear neutrophils, accumulates within ischemic myocardium and has been linked to adverse left ventricular remodeling. OBJECTIVE To reveal the role of myeloperoxidase for the development of ventricular arrhythmias. METHODS AND RESULTS In different murine models of myocardial ischemia, myeloperoxidase deficiency profoundly decreased vulnerability for ventricular tachycardia on programmed right ventricular and burst stimulation and spontaneously as assessed by ECG telemetry after isoproterenol injection. Experiments using CD11b/CD18 integrin-deficient (CD11b-/-) mice and intravenous myeloperoxidase infusion revealed that neutrophil infiltration is a prerequisite for myocardial myeloperoxidase accumulation. Ventricles from myeloperoxidase-deficient (Mpo-/-) mice showed less pronounced slowing and decreased heterogeneity of electric conduction in the peri-infarct zone than wild-type mice. Expression of the redox-sensitive gap junctional protein Cx43 (Connexin 43) was reduced in the peri-infarct area of wild-type compared with Mpo-/- mice. In isolated wild-type cardiomyocytes, Cx43 protein content decreased on myeloperoxidase/H2O2 incubation. Mapping of induced pluripotent stem cell-derived cardiomyocyte networks and in vivo investigations linked Cx43 breakdown to myeloperoxidase-dependent activation of matrix metalloproteinase 7. Moreover, Mpo-/- mice showed decreased ventricular postischemic fibrosis reflecting reduced accumulation of myofibroblasts. Ex vivo, myeloperoxidase was demonstrated to induce fibroblast-to-myofibroblast transdifferentiation by activation of p38 mitogen-activated protein kinases resulting in upregulated collagen generation. In support of our experimental findings, baseline myeloperoxidase plasma levels were independently associated with a history of ventricular arrhythmias, sudden cardiac death, or implantable cardioverter-defibrillator implantation in a cohort of 2622 stable patients with an ejection fraction >35% undergoing elective diagnostic cardiac evaluation. CONCLUSIONS Myeloperoxidase emerges as a crucial mediator of postischemic myocardial remodeling and may evolve as a novel pharmacological target for secondary disease prevention after myocardial ischemia.
Collapse
Affiliation(s)
- Martin Mollenhauer
- From the Cardiology, Heart Center (M.M., K.F., M.L., J.G., L.R., C.K., J.S., T.R., M.M., M.H., G.P., D.M., M.A., K.M., T.K.R., S.B., A.K., V.R.), Center for Molecular Medicine Cologne (M.M., K.F., M.L., J.G., L.R., C.K., J.S., T.R., M.M., M.H., G.P., D.M., M.A., K.M., T.K.R., S.B., A.K., V.R.), and Center for Physiology and Pathophysiology, Institute for Neurophysiology, Medical Faculty (T.S.), University of Cologne, Germany; University Heart Center Hamburg, Germany (J.K., D.L.); General and Interventional Cardiology (F.G.D.) and Experimental Pharmacology and Toxicology (B.G., T.E.), University Heart Center Hamburg, University Hospital Hamburg-Eppendorf (UKE), Germany; Institute of Biophysics, Czech Academy of Sciences, Brno (L.K.); International Clinical Research Center, St. Anne's University Hospital Brno, Czech Republic (L.K., A.K.); Mathematics, Cleveland State University, OH (Y.W.); and Cellular and Molecular Medicine and Cardiovascular Medicine, Cleveland Clinic, OH (W.H.W.T., S.L.H.)
| | - Kai Friedrichs
- From the Cardiology, Heart Center (M.M., K.F., M.L., J.G., L.R., C.K., J.S., T.R., M.M., M.H., G.P., D.M., M.A., K.M., T.K.R., S.B., A.K., V.R.), Center for Molecular Medicine Cologne (M.M., K.F., M.L., J.G., L.R., C.K., J.S., T.R., M.M., M.H., G.P., D.M., M.A., K.M., T.K.R., S.B., A.K., V.R.), and Center for Physiology and Pathophysiology, Institute for Neurophysiology, Medical Faculty (T.S.), University of Cologne, Germany; University Heart Center Hamburg, Germany (J.K., D.L.); General and Interventional Cardiology (F.G.D.) and Experimental Pharmacology and Toxicology (B.G., T.E.), University Heart Center Hamburg, University Hospital Hamburg-Eppendorf (UKE), Germany; Institute of Biophysics, Czech Academy of Sciences, Brno (L.K.); International Clinical Research Center, St. Anne's University Hospital Brno, Czech Republic (L.K., A.K.); Mathematics, Cleveland State University, OH (Y.W.); and Cellular and Molecular Medicine and Cardiovascular Medicine, Cleveland Clinic, OH (W.H.W.T., S.L.H.)
| | - Max Lange
- From the Cardiology, Heart Center (M.M., K.F., M.L., J.G., L.R., C.K., J.S., T.R., M.M., M.H., G.P., D.M., M.A., K.M., T.K.R., S.B., A.K., V.R.), Center for Molecular Medicine Cologne (M.M., K.F., M.L., J.G., L.R., C.K., J.S., T.R., M.M., M.H., G.P., D.M., M.A., K.M., T.K.R., S.B., A.K., V.R.), and Center for Physiology and Pathophysiology, Institute for Neurophysiology, Medical Faculty (T.S.), University of Cologne, Germany; University Heart Center Hamburg, Germany (J.K., D.L.); General and Interventional Cardiology (F.G.D.) and Experimental Pharmacology and Toxicology (B.G., T.E.), University Heart Center Hamburg, University Hospital Hamburg-Eppendorf (UKE), Germany; Institute of Biophysics, Czech Academy of Sciences, Brno (L.K.); International Clinical Research Center, St. Anne's University Hospital Brno, Czech Republic (L.K., A.K.); Mathematics, Cleveland State University, OH (Y.W.); and Cellular and Molecular Medicine and Cardiovascular Medicine, Cleveland Clinic, OH (W.H.W.T., S.L.H.)
| | - Jan Gesenberg
- From the Cardiology, Heart Center (M.M., K.F., M.L., J.G., L.R., C.K., J.S., T.R., M.M., M.H., G.P., D.M., M.A., K.M., T.K.R., S.B., A.K., V.R.), Center for Molecular Medicine Cologne (M.M., K.F., M.L., J.G., L.R., C.K., J.S., T.R., M.M., M.H., G.P., D.M., M.A., K.M., T.K.R., S.B., A.K., V.R.), and Center for Physiology and Pathophysiology, Institute for Neurophysiology, Medical Faculty (T.S.), University of Cologne, Germany; University Heart Center Hamburg, Germany (J.K., D.L.); General and Interventional Cardiology (F.G.D.) and Experimental Pharmacology and Toxicology (B.G., T.E.), University Heart Center Hamburg, University Hospital Hamburg-Eppendorf (UKE), Germany; Institute of Biophysics, Czech Academy of Sciences, Brno (L.K.); International Clinical Research Center, St. Anne's University Hospital Brno, Czech Republic (L.K., A.K.); Mathematics, Cleveland State University, OH (Y.W.); and Cellular and Molecular Medicine and Cardiovascular Medicine, Cleveland Clinic, OH (W.H.W.T., S.L.H.)
| | - Lisa Remane
- From the Cardiology, Heart Center (M.M., K.F., M.L., J.G., L.R., C.K., J.S., T.R., M.M., M.H., G.P., D.M., M.A., K.M., T.K.R., S.B., A.K., V.R.), Center for Molecular Medicine Cologne (M.M., K.F., M.L., J.G., L.R., C.K., J.S., T.R., M.M., M.H., G.P., D.M., M.A., K.M., T.K.R., S.B., A.K., V.R.), and Center for Physiology and Pathophysiology, Institute for Neurophysiology, Medical Faculty (T.S.), University of Cologne, Germany; University Heart Center Hamburg, Germany (J.K., D.L.); General and Interventional Cardiology (F.G.D.) and Experimental Pharmacology and Toxicology (B.G., T.E.), University Heart Center Hamburg, University Hospital Hamburg-Eppendorf (UKE), Germany; Institute of Biophysics, Czech Academy of Sciences, Brno (L.K.); International Clinical Research Center, St. Anne's University Hospital Brno, Czech Republic (L.K., A.K.); Mathematics, Cleveland State University, OH (Y.W.); and Cellular and Molecular Medicine and Cardiovascular Medicine, Cleveland Clinic, OH (W.H.W.T., S.L.H.)
| | - Christina Kerkenpaß
- From the Cardiology, Heart Center (M.M., K.F., M.L., J.G., L.R., C.K., J.S., T.R., M.M., M.H., G.P., D.M., M.A., K.M., T.K.R., S.B., A.K., V.R.), Center for Molecular Medicine Cologne (M.M., K.F., M.L., J.G., L.R., C.K., J.S., T.R., M.M., M.H., G.P., D.M., M.A., K.M., T.K.R., S.B., A.K., V.R.), and Center for Physiology and Pathophysiology, Institute for Neurophysiology, Medical Faculty (T.S.), University of Cologne, Germany; University Heart Center Hamburg, Germany (J.K., D.L.); General and Interventional Cardiology (F.G.D.) and Experimental Pharmacology and Toxicology (B.G., T.E.), University Heart Center Hamburg, University Hospital Hamburg-Eppendorf (UKE), Germany; Institute of Biophysics, Czech Academy of Sciences, Brno (L.K.); International Clinical Research Center, St. Anne's University Hospital Brno, Czech Republic (L.K., A.K.); Mathematics, Cleveland State University, OH (Y.W.); and Cellular and Molecular Medicine and Cardiovascular Medicine, Cleveland Clinic, OH (W.H.W.T., S.L.H.)
| | - Jenny Krause
- From the Cardiology, Heart Center (M.M., K.F., M.L., J.G., L.R., C.K., J.S., T.R., M.M., M.H., G.P., D.M., M.A., K.M., T.K.R., S.B., A.K., V.R.), Center for Molecular Medicine Cologne (M.M., K.F., M.L., J.G., L.R., C.K., J.S., T.R., M.M., M.H., G.P., D.M., M.A., K.M., T.K.R., S.B., A.K., V.R.), and Center for Physiology and Pathophysiology, Institute for Neurophysiology, Medical Faculty (T.S.), University of Cologne, Germany; University Heart Center Hamburg, Germany (J.K., D.L.); General and Interventional Cardiology (F.G.D.) and Experimental Pharmacology and Toxicology (B.G., T.E.), University Heart Center Hamburg, University Hospital Hamburg-Eppendorf (UKE), Germany; Institute of Biophysics, Czech Academy of Sciences, Brno (L.K.); International Clinical Research Center, St. Anne's University Hospital Brno, Czech Republic (L.K., A.K.); Mathematics, Cleveland State University, OH (Y.W.); and Cellular and Molecular Medicine and Cardiovascular Medicine, Cleveland Clinic, OH (W.H.W.T., S.L.H.)
| | - Johanna Schneider
- From the Cardiology, Heart Center (M.M., K.F., M.L., J.G., L.R., C.K., J.S., T.R., M.M., M.H., G.P., D.M., M.A., K.M., T.K.R., S.B., A.K., V.R.), Center for Molecular Medicine Cologne (M.M., K.F., M.L., J.G., L.R., C.K., J.S., T.R., M.M., M.H., G.P., D.M., M.A., K.M., T.K.R., S.B., A.K., V.R.), and Center for Physiology and Pathophysiology, Institute for Neurophysiology, Medical Faculty (T.S.), University of Cologne, Germany; University Heart Center Hamburg, Germany (J.K., D.L.); General and Interventional Cardiology (F.G.D.) and Experimental Pharmacology and Toxicology (B.G., T.E.), University Heart Center Hamburg, University Hospital Hamburg-Eppendorf (UKE), Germany; Institute of Biophysics, Czech Academy of Sciences, Brno (L.K.); International Clinical Research Center, St. Anne's University Hospital Brno, Czech Republic (L.K., A.K.); Mathematics, Cleveland State University, OH (Y.W.); and Cellular and Molecular Medicine and Cardiovascular Medicine, Cleveland Clinic, OH (W.H.W.T., S.L.H.)
| | - Thorben Ravekes
- From the Cardiology, Heart Center (M.M., K.F., M.L., J.G., L.R., C.K., J.S., T.R., M.M., M.H., G.P., D.M., M.A., K.M., T.K.R., S.B., A.K., V.R.), Center for Molecular Medicine Cologne (M.M., K.F., M.L., J.G., L.R., C.K., J.S., T.R., M.M., M.H., G.P., D.M., M.A., K.M., T.K.R., S.B., A.K., V.R.), and Center for Physiology and Pathophysiology, Institute for Neurophysiology, Medical Faculty (T.S.), University of Cologne, Germany; University Heart Center Hamburg, Germany (J.K., D.L.); General and Interventional Cardiology (F.G.D.) and Experimental Pharmacology and Toxicology (B.G., T.E.), University Heart Center Hamburg, University Hospital Hamburg-Eppendorf (UKE), Germany; Institute of Biophysics, Czech Academy of Sciences, Brno (L.K.); International Clinical Research Center, St. Anne's University Hospital Brno, Czech Republic (L.K., A.K.); Mathematics, Cleveland State University, OH (Y.W.); and Cellular and Molecular Medicine and Cardiovascular Medicine, Cleveland Clinic, OH (W.H.W.T., S.L.H.)
| | - Martina Maass
- From the Cardiology, Heart Center (M.M., K.F., M.L., J.G., L.R., C.K., J.S., T.R., M.M., M.H., G.P., D.M., M.A., K.M., T.K.R., S.B., A.K., V.R.), Center for Molecular Medicine Cologne (M.M., K.F., M.L., J.G., L.R., C.K., J.S., T.R., M.M., M.H., G.P., D.M., M.A., K.M., T.K.R., S.B., A.K., V.R.), and Center for Physiology and Pathophysiology, Institute for Neurophysiology, Medical Faculty (T.S.), University of Cologne, Germany; University Heart Center Hamburg, Germany (J.K., D.L.); General and Interventional Cardiology (F.G.D.) and Experimental Pharmacology and Toxicology (B.G., T.E.), University Heart Center Hamburg, University Hospital Hamburg-Eppendorf (UKE), Germany; Institute of Biophysics, Czech Academy of Sciences, Brno (L.K.); International Clinical Research Center, St. Anne's University Hospital Brno, Czech Republic (L.K., A.K.); Mathematics, Cleveland State University, OH (Y.W.); and Cellular and Molecular Medicine and Cardiovascular Medicine, Cleveland Clinic, OH (W.H.W.T., S.L.H.)
| | - Marcel Halbach
- From the Cardiology, Heart Center (M.M., K.F., M.L., J.G., L.R., C.K., J.S., T.R., M.M., M.H., G.P., D.M., M.A., K.M., T.K.R., S.B., A.K., V.R.), Center for Molecular Medicine Cologne (M.M., K.F., M.L., J.G., L.R., C.K., J.S., T.R., M.M., M.H., G.P., D.M., M.A., K.M., T.K.R., S.B., A.K., V.R.), and Center for Physiology and Pathophysiology, Institute for Neurophysiology, Medical Faculty (T.S.), University of Cologne, Germany; University Heart Center Hamburg, Germany (J.K., D.L.); General and Interventional Cardiology (F.G.D.) and Experimental Pharmacology and Toxicology (B.G., T.E.), University Heart Center Hamburg, University Hospital Hamburg-Eppendorf (UKE), Germany; Institute of Biophysics, Czech Academy of Sciences, Brno (L.K.); International Clinical Research Center, St. Anne's University Hospital Brno, Czech Republic (L.K., A.K.); Mathematics, Cleveland State University, OH (Y.W.); and Cellular and Molecular Medicine and Cardiovascular Medicine, Cleveland Clinic, OH (W.H.W.T., S.L.H.)
| | - Gabriel Peinkofer
- From the Cardiology, Heart Center (M.M., K.F., M.L., J.G., L.R., C.K., J.S., T.R., M.M., M.H., G.P., D.M., M.A., K.M., T.K.R., S.B., A.K., V.R.), Center for Molecular Medicine Cologne (M.M., K.F., M.L., J.G., L.R., C.K., J.S., T.R., M.M., M.H., G.P., D.M., M.A., K.M., T.K.R., S.B., A.K., V.R.), and Center for Physiology and Pathophysiology, Institute for Neurophysiology, Medical Faculty (T.S.), University of Cologne, Germany; University Heart Center Hamburg, Germany (J.K., D.L.); General and Interventional Cardiology (F.G.D.) and Experimental Pharmacology and Toxicology (B.G., T.E.), University Heart Center Hamburg, University Hospital Hamburg-Eppendorf (UKE), Germany; Institute of Biophysics, Czech Academy of Sciences, Brno (L.K.); International Clinical Research Center, St. Anne's University Hospital Brno, Czech Republic (L.K., A.K.); Mathematics, Cleveland State University, OH (Y.W.); and Cellular and Molecular Medicine and Cardiovascular Medicine, Cleveland Clinic, OH (W.H.W.T., S.L.H.)
| | - Tomo Saric
- From the Cardiology, Heart Center (M.M., K.F., M.L., J.G., L.R., C.K., J.S., T.R., M.M., M.H., G.P., D.M., M.A., K.M., T.K.R., S.B., A.K., V.R.), Center for Molecular Medicine Cologne (M.M., K.F., M.L., J.G., L.R., C.K., J.S., T.R., M.M., M.H., G.P., D.M., M.A., K.M., T.K.R., S.B., A.K., V.R.), and Center for Physiology and Pathophysiology, Institute for Neurophysiology, Medical Faculty (T.S.), University of Cologne, Germany; University Heart Center Hamburg, Germany (J.K., D.L.); General and Interventional Cardiology (F.G.D.) and Experimental Pharmacology and Toxicology (B.G., T.E.), University Heart Center Hamburg, University Hospital Hamburg-Eppendorf (UKE), Germany; Institute of Biophysics, Czech Academy of Sciences, Brno (L.K.); International Clinical Research Center, St. Anne's University Hospital Brno, Czech Republic (L.K., A.K.); Mathematics, Cleveland State University, OH (Y.W.); and Cellular and Molecular Medicine and Cardiovascular Medicine, Cleveland Clinic, OH (W.H.W.T., S.L.H.)
| | - Dennis Mehrkens
- From the Cardiology, Heart Center (M.M., K.F., M.L., J.G., L.R., C.K., J.S., T.R., M.M., M.H., G.P., D.M., M.A., K.M., T.K.R., S.B., A.K., V.R.), Center for Molecular Medicine Cologne (M.M., K.F., M.L., J.G., L.R., C.K., J.S., T.R., M.M., M.H., G.P., D.M., M.A., K.M., T.K.R., S.B., A.K., V.R.), and Center for Physiology and Pathophysiology, Institute for Neurophysiology, Medical Faculty (T.S.), University of Cologne, Germany; University Heart Center Hamburg, Germany (J.K., D.L.); General and Interventional Cardiology (F.G.D.) and Experimental Pharmacology and Toxicology (B.G., T.E.), University Heart Center Hamburg, University Hospital Hamburg-Eppendorf (UKE), Germany; Institute of Biophysics, Czech Academy of Sciences, Brno (L.K.); International Clinical Research Center, St. Anne's University Hospital Brno, Czech Republic (L.K., A.K.); Mathematics, Cleveland State University, OH (Y.W.); and Cellular and Molecular Medicine and Cardiovascular Medicine, Cleveland Clinic, OH (W.H.W.T., S.L.H.)
| | - Matti Adam
- From the Cardiology, Heart Center (M.M., K.F., M.L., J.G., L.R., C.K., J.S., T.R., M.M., M.H., G.P., D.M., M.A., K.M., T.K.R., S.B., A.K., V.R.), Center for Molecular Medicine Cologne (M.M., K.F., M.L., J.G., L.R., C.K., J.S., T.R., M.M., M.H., G.P., D.M., M.A., K.M., T.K.R., S.B., A.K., V.R.), and Center for Physiology and Pathophysiology, Institute for Neurophysiology, Medical Faculty (T.S.), University of Cologne, Germany; University Heart Center Hamburg, Germany (J.K., D.L.); General and Interventional Cardiology (F.G.D.) and Experimental Pharmacology and Toxicology (B.G., T.E.), University Heart Center Hamburg, University Hospital Hamburg-Eppendorf (UKE), Germany; Institute of Biophysics, Czech Academy of Sciences, Brno (L.K.); International Clinical Research Center, St. Anne's University Hospital Brno, Czech Republic (L.K., A.K.); Mathematics, Cleveland State University, OH (Y.W.); and Cellular and Molecular Medicine and Cardiovascular Medicine, Cleveland Clinic, OH (W.H.W.T., S.L.H.)
| | - Florian G Deuschl
- From the Cardiology, Heart Center (M.M., K.F., M.L., J.G., L.R., C.K., J.S., T.R., M.M., M.H., G.P., D.M., M.A., K.M., T.K.R., S.B., A.K., V.R.), Center for Molecular Medicine Cologne (M.M., K.F., M.L., J.G., L.R., C.K., J.S., T.R., M.M., M.H., G.P., D.M., M.A., K.M., T.K.R., S.B., A.K., V.R.), and Center for Physiology and Pathophysiology, Institute for Neurophysiology, Medical Faculty (T.S.), University of Cologne, Germany; University Heart Center Hamburg, Germany (J.K., D.L.); General and Interventional Cardiology (F.G.D.) and Experimental Pharmacology and Toxicology (B.G., T.E.), University Heart Center Hamburg, University Hospital Hamburg-Eppendorf (UKE), Germany; Institute of Biophysics, Czech Academy of Sciences, Brno (L.K.); International Clinical Research Center, St. Anne's University Hospital Brno, Czech Republic (L.K., A.K.); Mathematics, Cleveland State University, OH (Y.W.); and Cellular and Molecular Medicine and Cardiovascular Medicine, Cleveland Clinic, OH (W.H.W.T., S.L.H.)
| | - Denise Lau
- From the Cardiology, Heart Center (M.M., K.F., M.L., J.G., L.R., C.K., J.S., T.R., M.M., M.H., G.P., D.M., M.A., K.M., T.K.R., S.B., A.K., V.R.), Center for Molecular Medicine Cologne (M.M., K.F., M.L., J.G., L.R., C.K., J.S., T.R., M.M., M.H., G.P., D.M., M.A., K.M., T.K.R., S.B., A.K., V.R.), and Center for Physiology and Pathophysiology, Institute for Neurophysiology, Medical Faculty (T.S.), University of Cologne, Germany; University Heart Center Hamburg, Germany (J.K., D.L.); General and Interventional Cardiology (F.G.D.) and Experimental Pharmacology and Toxicology (B.G., T.E.), University Heart Center Hamburg, University Hospital Hamburg-Eppendorf (UKE), Germany; Institute of Biophysics, Czech Academy of Sciences, Brno (L.K.); International Clinical Research Center, St. Anne's University Hospital Brno, Czech Republic (L.K., A.K.); Mathematics, Cleveland State University, OH (Y.W.); and Cellular and Molecular Medicine and Cardiovascular Medicine, Cleveland Clinic, OH (W.H.W.T., S.L.H.)
| | - Birgit Geertz
- From the Cardiology, Heart Center (M.M., K.F., M.L., J.G., L.R., C.K., J.S., T.R., M.M., M.H., G.P., D.M., M.A., K.M., T.K.R., S.B., A.K., V.R.), Center for Molecular Medicine Cologne (M.M., K.F., M.L., J.G., L.R., C.K., J.S., T.R., M.M., M.H., G.P., D.M., M.A., K.M., T.K.R., S.B., A.K., V.R.), and Center for Physiology and Pathophysiology, Institute for Neurophysiology, Medical Faculty (T.S.), University of Cologne, Germany; University Heart Center Hamburg, Germany (J.K., D.L.); General and Interventional Cardiology (F.G.D.) and Experimental Pharmacology and Toxicology (B.G., T.E.), University Heart Center Hamburg, University Hospital Hamburg-Eppendorf (UKE), Germany; Institute of Biophysics, Czech Academy of Sciences, Brno (L.K.); International Clinical Research Center, St. Anne's University Hospital Brno, Czech Republic (L.K., A.K.); Mathematics, Cleveland State University, OH (Y.W.); and Cellular and Molecular Medicine and Cardiovascular Medicine, Cleveland Clinic, OH (W.H.W.T., S.L.H.)
| | - Kashish Manchanda
- From the Cardiology, Heart Center (M.M., K.F., M.L., J.G., L.R., C.K., J.S., T.R., M.M., M.H., G.P., D.M., M.A., K.M., T.K.R., S.B., A.K., V.R.), Center for Molecular Medicine Cologne (M.M., K.F., M.L., J.G., L.R., C.K., J.S., T.R., M.M., M.H., G.P., D.M., M.A., K.M., T.K.R., S.B., A.K., V.R.), and Center for Physiology and Pathophysiology, Institute for Neurophysiology, Medical Faculty (T.S.), University of Cologne, Germany; University Heart Center Hamburg, Germany (J.K., D.L.); General and Interventional Cardiology (F.G.D.) and Experimental Pharmacology and Toxicology (B.G., T.E.), University Heart Center Hamburg, University Hospital Hamburg-Eppendorf (UKE), Germany; Institute of Biophysics, Czech Academy of Sciences, Brno (L.K.); International Clinical Research Center, St. Anne's University Hospital Brno, Czech Republic (L.K., A.K.); Mathematics, Cleveland State University, OH (Y.W.); and Cellular and Molecular Medicine and Cardiovascular Medicine, Cleveland Clinic, OH (W.H.W.T., S.L.H.)
| | - Thomas Eschenhagen
- From the Cardiology, Heart Center (M.M., K.F., M.L., J.G., L.R., C.K., J.S., T.R., M.M., M.H., G.P., D.M., M.A., K.M., T.K.R., S.B., A.K., V.R.), Center for Molecular Medicine Cologne (M.M., K.F., M.L., J.G., L.R., C.K., J.S., T.R., M.M., M.H., G.P., D.M., M.A., K.M., T.K.R., S.B., A.K., V.R.), and Center for Physiology and Pathophysiology, Institute for Neurophysiology, Medical Faculty (T.S.), University of Cologne, Germany; University Heart Center Hamburg, Germany (J.K., D.L.); General and Interventional Cardiology (F.G.D.) and Experimental Pharmacology and Toxicology (B.G., T.E.), University Heart Center Hamburg, University Hospital Hamburg-Eppendorf (UKE), Germany; Institute of Biophysics, Czech Academy of Sciences, Brno (L.K.); International Clinical Research Center, St. Anne's University Hospital Brno, Czech Republic (L.K., A.K.); Mathematics, Cleveland State University, OH (Y.W.); and Cellular and Molecular Medicine and Cardiovascular Medicine, Cleveland Clinic, OH (W.H.W.T., S.L.H.)
| | - Lukas Kubala
- From the Cardiology, Heart Center (M.M., K.F., M.L., J.G., L.R., C.K., J.S., T.R., M.M., M.H., G.P., D.M., M.A., K.M., T.K.R., S.B., A.K., V.R.), Center for Molecular Medicine Cologne (M.M., K.F., M.L., J.G., L.R., C.K., J.S., T.R., M.M., M.H., G.P., D.M., M.A., K.M., T.K.R., S.B., A.K., V.R.), and Center for Physiology and Pathophysiology, Institute for Neurophysiology, Medical Faculty (T.S.), University of Cologne, Germany; University Heart Center Hamburg, Germany (J.K., D.L.); General and Interventional Cardiology (F.G.D.) and Experimental Pharmacology and Toxicology (B.G., T.E.), University Heart Center Hamburg, University Hospital Hamburg-Eppendorf (UKE), Germany; Institute of Biophysics, Czech Academy of Sciences, Brno (L.K.); International Clinical Research Center, St. Anne's University Hospital Brno, Czech Republic (L.K., A.K.); Mathematics, Cleveland State University, OH (Y.W.); and Cellular and Molecular Medicine and Cardiovascular Medicine, Cleveland Clinic, OH (W.H.W.T., S.L.H.)
| | - Tanja K Rudolph
- From the Cardiology, Heart Center (M.M., K.F., M.L., J.G., L.R., C.K., J.S., T.R., M.M., M.H., G.P., D.M., M.A., K.M., T.K.R., S.B., A.K., V.R.), Center for Molecular Medicine Cologne (M.M., K.F., M.L., J.G., L.R., C.K., J.S., T.R., M.M., M.H., G.P., D.M., M.A., K.M., T.K.R., S.B., A.K., V.R.), and Center for Physiology and Pathophysiology, Institute for Neurophysiology, Medical Faculty (T.S.), University of Cologne, Germany; University Heart Center Hamburg, Germany (J.K., D.L.); General and Interventional Cardiology (F.G.D.) and Experimental Pharmacology and Toxicology (B.G., T.E.), University Heart Center Hamburg, University Hospital Hamburg-Eppendorf (UKE), Germany; Institute of Biophysics, Czech Academy of Sciences, Brno (L.K.); International Clinical Research Center, St. Anne's University Hospital Brno, Czech Republic (L.K., A.K.); Mathematics, Cleveland State University, OH (Y.W.); and Cellular and Molecular Medicine and Cardiovascular Medicine, Cleveland Clinic, OH (W.H.W.T., S.L.H.)
| | - Yuping Wu
- From the Cardiology, Heart Center (M.M., K.F., M.L., J.G., L.R., C.K., J.S., T.R., M.M., M.H., G.P., D.M., M.A., K.M., T.K.R., S.B., A.K., V.R.), Center for Molecular Medicine Cologne (M.M., K.F., M.L., J.G., L.R., C.K., J.S., T.R., M.M., M.H., G.P., D.M., M.A., K.M., T.K.R., S.B., A.K., V.R.), and Center for Physiology and Pathophysiology, Institute for Neurophysiology, Medical Faculty (T.S.), University of Cologne, Germany; University Heart Center Hamburg, Germany (J.K., D.L.); General and Interventional Cardiology (F.G.D.) and Experimental Pharmacology and Toxicology (B.G., T.E.), University Heart Center Hamburg, University Hospital Hamburg-Eppendorf (UKE), Germany; Institute of Biophysics, Czech Academy of Sciences, Brno (L.K.); International Clinical Research Center, St. Anne's University Hospital Brno, Czech Republic (L.K., A.K.); Mathematics, Cleveland State University, OH (Y.W.); and Cellular and Molecular Medicine and Cardiovascular Medicine, Cleveland Clinic, OH (W.H.W.T., S.L.H.)
| | - W H Wilson Tang
- From the Cardiology, Heart Center (M.M., K.F., M.L., J.G., L.R., C.K., J.S., T.R., M.M., M.H., G.P., D.M., M.A., K.M., T.K.R., S.B., A.K., V.R.), Center for Molecular Medicine Cologne (M.M., K.F., M.L., J.G., L.R., C.K., J.S., T.R., M.M., M.H., G.P., D.M., M.A., K.M., T.K.R., S.B., A.K., V.R.), and Center for Physiology and Pathophysiology, Institute for Neurophysiology, Medical Faculty (T.S.), University of Cologne, Germany; University Heart Center Hamburg, Germany (J.K., D.L.); General and Interventional Cardiology (F.G.D.) and Experimental Pharmacology and Toxicology (B.G., T.E.), University Heart Center Hamburg, University Hospital Hamburg-Eppendorf (UKE), Germany; Institute of Biophysics, Czech Academy of Sciences, Brno (L.K.); International Clinical Research Center, St. Anne's University Hospital Brno, Czech Republic (L.K., A.K.); Mathematics, Cleveland State University, OH (Y.W.); and Cellular and Molecular Medicine and Cardiovascular Medicine, Cleveland Clinic, OH (W.H.W.T., S.L.H.)
| | - Stanley L Hazen
- From the Cardiology, Heart Center (M.M., K.F., M.L., J.G., L.R., C.K., J.S., T.R., M.M., M.H., G.P., D.M., M.A., K.M., T.K.R., S.B., A.K., V.R.), Center for Molecular Medicine Cologne (M.M., K.F., M.L., J.G., L.R., C.K., J.S., T.R., M.M., M.H., G.P., D.M., M.A., K.M., T.K.R., S.B., A.K., V.R.), and Center for Physiology and Pathophysiology, Institute for Neurophysiology, Medical Faculty (T.S.), University of Cologne, Germany; University Heart Center Hamburg, Germany (J.K., D.L.); General and Interventional Cardiology (F.G.D.) and Experimental Pharmacology and Toxicology (B.G., T.E.), University Heart Center Hamburg, University Hospital Hamburg-Eppendorf (UKE), Germany; Institute of Biophysics, Czech Academy of Sciences, Brno (L.K.); International Clinical Research Center, St. Anne's University Hospital Brno, Czech Republic (L.K., A.K.); Mathematics, Cleveland State University, OH (Y.W.); and Cellular and Molecular Medicine and Cardiovascular Medicine, Cleveland Clinic, OH (W.H.W.T., S.L.H.)
| | - Stephan Baldus
- From the Cardiology, Heart Center (M.M., K.F., M.L., J.G., L.R., C.K., J.S., T.R., M.M., M.H., G.P., D.M., M.A., K.M., T.K.R., S.B., A.K., V.R.), Center for Molecular Medicine Cologne (M.M., K.F., M.L., J.G., L.R., C.K., J.S., T.R., M.M., M.H., G.P., D.M., M.A., K.M., T.K.R., S.B., A.K., V.R.), and Center for Physiology and Pathophysiology, Institute for Neurophysiology, Medical Faculty (T.S.), University of Cologne, Germany; University Heart Center Hamburg, Germany (J.K., D.L.); General and Interventional Cardiology (F.G.D.) and Experimental Pharmacology and Toxicology (B.G., T.E.), University Heart Center Hamburg, University Hospital Hamburg-Eppendorf (UKE), Germany; Institute of Biophysics, Czech Academy of Sciences, Brno (L.K.); International Clinical Research Center, St. Anne's University Hospital Brno, Czech Republic (L.K., A.K.); Mathematics, Cleveland State University, OH (Y.W.); and Cellular and Molecular Medicine and Cardiovascular Medicine, Cleveland Clinic, OH (W.H.W.T., S.L.H.)
| | - Anna Klinke
- From the Cardiology, Heart Center (M.M., K.F., M.L., J.G., L.R., C.K., J.S., T.R., M.M., M.H., G.P., D.M., M.A., K.M., T.K.R., S.B., A.K., V.R.), Center for Molecular Medicine Cologne (M.M., K.F., M.L., J.G., L.R., C.K., J.S., T.R., M.M., M.H., G.P., D.M., M.A., K.M., T.K.R., S.B., A.K., V.R.), and Center for Physiology and Pathophysiology, Institute for Neurophysiology, Medical Faculty (T.S.), University of Cologne, Germany; University Heart Center Hamburg, Germany (J.K., D.L.); General and Interventional Cardiology (F.G.D.) and Experimental Pharmacology and Toxicology (B.G., T.E.), University Heart Center Hamburg, University Hospital Hamburg-Eppendorf (UKE), Germany; Institute of Biophysics, Czech Academy of Sciences, Brno (L.K.); International Clinical Research Center, St. Anne's University Hospital Brno, Czech Republic (L.K., A.K.); Mathematics, Cleveland State University, OH (Y.W.); and Cellular and Molecular Medicine and Cardiovascular Medicine, Cleveland Clinic, OH (W.H.W.T., S.L.H.)
| | - Volker Rudolph
- From the Cardiology, Heart Center (M.M., K.F., M.L., J.G., L.R., C.K., J.S., T.R., M.M., M.H., G.P., D.M., M.A., K.M., T.K.R., S.B., A.K., V.R.), Center for Molecular Medicine Cologne (M.M., K.F., M.L., J.G., L.R., C.K., J.S., T.R., M.M., M.H., G.P., D.M., M.A., K.M., T.K.R., S.B., A.K., V.R.), and Center for Physiology and Pathophysiology, Institute for Neurophysiology, Medical Faculty (T.S.), University of Cologne, Germany; University Heart Center Hamburg, Germany (J.K., D.L.); General and Interventional Cardiology (F.G.D.) and Experimental Pharmacology and Toxicology (B.G., T.E.), University Heart Center Hamburg, University Hospital Hamburg-Eppendorf (UKE), Germany; Institute of Biophysics, Czech Academy of Sciences, Brno (L.K.); International Clinical Research Center, St. Anne's University Hospital Brno, Czech Republic (L.K., A.K.); Mathematics, Cleveland State University, OH (Y.W.); and Cellular and Molecular Medicine and Cardiovascular Medicine, Cleveland Clinic, OH (W.H.W.T., S.L.H.).
| |
Collapse
|
79
|
Daiber A, Steven S, Weber A, Shuvaev VV, Muzykantov VR, Laher I, Li H, Lamas S, Münzel T. Targeting vascular (endothelial) dysfunction. Br J Pharmacol 2017; 174:1591-1619. [PMID: 27187006 PMCID: PMC5446575 DOI: 10.1111/bph.13517] [Citation(s) in RCA: 304] [Impact Index Per Article: 43.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2015] [Revised: 04/28/2016] [Accepted: 05/09/2016] [Indexed: 12/18/2022] Open
Abstract
Cardiovascular diseases are major contributors to global deaths and disability-adjusted life years, with hypertension a significant risk factor for all causes of death. The endothelium that lines the inner wall of the vasculature regulates essential haemostatic functions, such as vascular tone, circulation of blood cells, inflammation and platelet activity. Endothelial dysfunction is an early predictor of atherosclerosis and future cardiovascular events. We review the prognostic value of obtaining measurements of endothelial function, the clinical techniques for its determination, the mechanisms leading to endothelial dysfunction and the therapeutic treatment of endothelial dysfunction. Since vascular oxidative stress and inflammation are major determinants of endothelial function, we have also addressed current antioxidant and anti-inflammatory therapies. In the light of recent data that dispute the prognostic value of endothelial function in healthy human cohorts, we also discuss alternative diagnostic parameters such as vascular stiffness index and intima/media thickness ratio. We also suggest that assessing vascular function, including that of smooth muscle and even perivascular adipose tissue, may be an appropriate parameter for clinical investigations. LINKED ARTICLES This article is part of a themed section on Redox Biology and Oxidative Stress in Health and Disease. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v174.12/issuetoc.
Collapse
Affiliation(s)
- Andreas Daiber
- Center of CardiologyMedical Center of the Johannes Gutenberg UniversityMainzGermany
- German Center for Cardiovascular Research (DZHK)Partner Site Rhine‐MainMainzGermany
| | - Sebastian Steven
- Center of CardiologyMedical Center of the Johannes Gutenberg UniversityMainzGermany
- Center of Thrombosis and HemostasisMedical Center of the Johannes Gutenberg UniversityMainzGermany
| | - Alina Weber
- Center of CardiologyMedical Center of the Johannes Gutenberg UniversityMainzGermany
| | - Vladimir V. Shuvaev
- Department of Systems Pharmacology & Translational Therapeutics, Perelman School of MedicineUniversity of PennsylvaniaPhiladelphiaPAUSA
| | - Vladimir R. Muzykantov
- Department of Systems Pharmacology & Translational Therapeutics, Perelman School of MedicineUniversity of PennsylvaniaPhiladelphiaPAUSA
| | - Ismail Laher
- Department of Pharmacology and Therapeutics, Faculty of MedicineUniversity of British ColumbiaVancouverBCCanada
| | - Huige Li
- German Center for Cardiovascular Research (DZHK)Partner Site Rhine‐MainMainzGermany
- Department of PharmacologyMedical Center of the Johannes Gutenberg UniversityMainzGermany
| | - Santiago Lamas
- Department of Cell Biology and ImmunologyCentro de Biología Molecular "Severo Ochoa" (CSIC‐UAM)MadridSpain
| | - Thomas Münzel
- Center of CardiologyMedical Center of the Johannes Gutenberg UniversityMainzGermany
- German Center for Cardiovascular Research (DZHK)Partner Site Rhine‐MainMainzGermany
| |
Collapse
|
80
|
Taeb M, Mortazavi-Jahromi SS, Jafarzadeh A, Mirzaei MR, Mirshafiey A. An in vitro evaluation of anti-aging effect of guluronic acid (G2013) based on enzymatic oxidative stress gene expression using healthy individuals PBMCs. Biomed Pharmacother 2017; 90:262-267. [DOI: 10.1016/j.biopha.2017.03.066] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2017] [Revised: 03/19/2017] [Accepted: 03/22/2017] [Indexed: 01/07/2023] Open
|
81
|
Kormi I, Nieminen MT, Havulinna AS, Zeller T, Blankenberg S, Tervahartiala T, Sorsa T, Salomaa V, Pussinen PJ. Matrix metalloproteinase-8 and tissue inhibitor of matrix metalloproteinase-1 predict incident cardiovascular disease events and all-cause mortality in a population-based cohort. Eur J Prev Cardiol 2017; 24:1136-1144. [PMID: 28429955 DOI: 10.1177/2047487317706585] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Background Extracellular matrix degrading proteases and their regulators play an important role in atherogenesis and subsequent plaque rupture leading to acute cardiovascular manifestations. Design and methods In this prospective cohort study, we investigated the prognostic value of circulating matrix metalloproteinase-8, tissue inhibitor of matrix metalloproteinase-1 concentrations, the ratio of matrix metalloproteinase-8/ tissue inhibitor of matrix metalloproteinase-1 and, for comparison, myeloperoxidase and C-reactive protein concentrations for incident cardiovascular disease endpoints. The population-based FINRISK97 cohort comprised 7928 persons without cardiovascular disease at baseline. The baseline survey included a clinical examination and blood sampling. During a 13-year follow-up the endpoints were ascertained through national healthcare registers. The associations of measured biomarkers with the endpoints, including cardiovascular disease event, coronary artery disease, acute myocardial infarction, stroke and all-cause death, were analysed using Cox regression models. Discrimination and reclassification models were used to evaluate the clinical implications of the biomarkers. Results Serum tissue inhibitor of matrix metalloproteinase-1 and C-reactive protein concentrations were associated significantly with increased risk for all studied endpoints. Additionally, matrix metalloproteinase-8 concentration was associated with the risk for a coronary artery disease event, myocardial infarction and death, and myeloperoxidase concentration with the risk for cardiovascular disease events, stroke and death. The only significant association for the matrix metalloproteinase-8/ tissue inhibitor of matrix metalloproteinase-1 ratio was observed with the risk for myocardial infarction. Adding tissue inhibitor of matrix metalloproteinase-1 to the established risk profile improved risk discrimination of myocardial infarction ( p=0.039) and death (0.001). Both matrix metalloproteinase-8 (5.2%, p < 0.001) and tissue inhibitor of matrix metalloproteinase-1 (12.9%, p < 0.001) provided significant clinical net reclassification improvement for death. Conclusions Serum matrix metalloproteinase-8 and tissue inhibitor of matrix metalloproteinase-1 can be considered as biomarkers of incident cardiovascular disease events and death.
Collapse
Affiliation(s)
- Immi Kormi
- 1 Oral and Maxillofacial Department, Oulu University Hospital, Finland
| | - Mikko T Nieminen
- 2 Oral and Maxillofacial Diseases, Helsinki University Hospital, Finland
| | | | - Tanja Zeller
- 4 Clinic for General and Interventional Cardiology, University Heart Center Hamburg, Germany.,5 German Center for Cardiovascular Research (DZHK e.V), Partner Site Hamburg/Lübeck/Kiel, Germany
| | - Stefan Blankenberg
- 4 Clinic for General and Interventional Cardiology, University Heart Center Hamburg, Germany.,5 German Center for Cardiovascular Research (DZHK e.V), Partner Site Hamburg/Lübeck/Kiel, Germany
| | | | - Timo Sorsa
- 2 Oral and Maxillofacial Diseases, Helsinki University Hospital, Finland.,6 Division of Periodontology, Karolinska Institutet, Sweden
| | | | - Pirkko J Pussinen
- 2 Oral and Maxillofacial Diseases, Helsinki University Hospital, Finland
| |
Collapse
|
82
|
Liu H, Zhang WJ, Long CF, Su WW. Protective effects of traditional Chinese herbal formula Compound Xueshuantong Capsule (CXC) on rats with blood circulation disorders. BIOTECHNOL BIOTEC EQ 2017. [DOI: 10.1080/13102818.2017.1301785] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
83
|
Calvani R, Marini F, Cesari M, Buford TW, Manini TM, Pahor M, Leeuwenburgh C, Bernabei R, Landi F, Marzetti E. Systemic inflammation, body composition, and physical performance in old community-dwellers. J Cachexia Sarcopenia Muscle 2017; 8:69-77. [PMID: 27897412 PMCID: PMC5326820 DOI: 10.1002/jcsm.12134] [Citation(s) in RCA: 43] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/23/2016] [Revised: 06/01/2016] [Accepted: 06/10/2016] [Indexed: 12/25/2022] Open
Abstract
BACKGROUND Chronic inflammation, changes in body composition, and declining physical function are hallmarks of the ageing process. The aim of the present study was to provide a preliminary characterisation of the relationship among these age-related phenomena via multivariate modelling. METHODS Thirty-five old adults (OAs) and 17 young adults (YAs) were enrolled. The volume of skeletal muscle, subcutaneous adipose tissue (SAT), and intermuscular adipose tissue (IMAT) of the thigh was quantified by three-dimensional magnetic resonance imaging. Muscle strength was measured by knee extension strength testing. In OAs, physical performance was further assessed via the Short Physical Performance Battery (SPPB). Multi-block partial least squares-discriminant analysis (PLS-DA) was employed to explore the relationship among inflammatory profiles and functional and imaging parameters. Double cross-validation procedures were used to validate the predictive ability of the PLS-DA model. RESULTS The optimal complexity of the PLS-DA model was found to be two latent variables. The proportion of correct classification was 92.3% in calibration (94.1% in YAs and 91.4% in OAs), 84.6% in internal validation (95.3% in YAs and 78.5% in OAs), and 82.6% in external validation (94% in YAs and 76.9% in OAs). Relative to YAs, OAs were characterised by smaller muscle volume, greater IMAT volume, lower muscle strength, and higher levels of myeloperoxidase, P-selectin, soluble intercellular adhesion molecule 1, and vascular cell adhesion molecule 1. Compared with OAs with SPPB >8, those scoring ≤8 were characterised by smaller muscle volume, greater SAT volume, lower muscle strength, and higher levels of interleukin 1 beta, 6, 10, 12, 13, tumour necrosis factor alpha, and granulocyte-macrophage colony-stimulating factor. CONCLUSIONS Multi-block PLS-DA identified distinct patterns of relationships among circulating cytokines and functional and imaging parameters in persons of different ages and varying levels of physical performance. The longitudinal implementation of such an innovative strategy could allow for the tracking of health status over time, the early detection of deviations in health trajectories, and the monitoring of response to treatments.
Collapse
Affiliation(s)
- Riccardo Calvani
- Department of Geriatrics, Neurosciences, and OrthopaedicsCatholic University of the Sacred HeartRomeItaly
| | - Federico Marini
- Department of Chemistry‘Sapienza’ University of RomeRomeItaly
| | - Matteo Cesari
- GérontopôleCentre Hospitalier Universitaire de ToulouseToulouseFrance
- Institut National de la Santé et de la Recherche Médicale (UMR1027)Université de Toulouse III Paul SabatierToulouseFrance
| | - Thomas W. Buford
- Department of Aging and GeriatricsUniversity of FloridaGainesvilleFLUSA
| | - Todd M. Manini
- Department of Aging and GeriatricsUniversity of FloridaGainesvilleFLUSA
| | - Marco Pahor
- Department of Aging and GeriatricsUniversity of FloridaGainesvilleFLUSA
| | | | - Roberto Bernabei
- Department of Geriatrics, Neurosciences, and OrthopaedicsCatholic University of the Sacred HeartRomeItaly
| | - Francesco Landi
- Department of Geriatrics, Neurosciences, and OrthopaedicsCatholic University of the Sacred HeartRomeItaly
| | - Emanuele Marzetti
- Department of Geriatrics, Neurosciences, and OrthopaedicsCatholic University of the Sacred HeartRomeItaly
| |
Collapse
|
84
|
Hansberry DR, Shah K, Agarwal P, Agarwal N. Fecal Myeloperoxidase as a Biomarker for Inflammatory Bowel Disease. Cureus 2017; 9:e1004. [PMID: 28286723 PMCID: PMC5332167 DOI: 10.7759/cureus.1004] [Citation(s) in RCA: 46] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023] Open
Abstract
Inflammatory bowel disease (IBD) is a chronic condition involving the inflammation of the colon and small intestine. IBD affects as many as 1.4 million people in the U.S. alone and costs the health care industry over $1.7 billion annually. Managing IBD normally requires invasive and often discomforting diagnostic tests. In an effort to alleviate the painful and costly nature of traditional diagnosis, there has been increasing research initiative focused on noninvasive biomarkers. PubMed, provided by the United States National Library of Medicine (NLM) at the National Institutes of Health, was utilized with the following search terms: 1) myeloperoxidase (MPO) 2), inflammatory bowel disease (IBD), and 3) neutrophils. The following terms were used interchangeably with search terms 1-3: 4) costs, 5) biomarkers, 6) review, and 7) etiology. In the context of IBD, myeloperoxidase (MPO), a lysosomal protein found in neutrophils, may serve as a viable biomarker for assessing disease status. Several studies demonstrated increased levels of neutrophils in patients with active IBD. Furthermore, studies have found significantly higher levels of MPO in patients with active IBD compared to patients without IBD as well as patients with inactive IBD. MPO is also expressed in higher concentrations in patients with more severe forms of IBD. When measuring treatment efficacy, MPO levels are indicative of the quality of response. MPO may serve as an important diagnostic and prognostic tool in assessing IBD status.
Collapse
Affiliation(s)
| | - Kush Shah
- Gastroenterology, Rowan University School of Osteopathic Medicine
| | - Prateek Agarwal
- Neurosurgery, Perelman School of Medicine at the University of Pennsylvania
| | - Nitin Agarwal
- Department of Neurological Surgery, University of Pittsburgh Medical Center
| |
Collapse
|
85
|
Ristovski-Kornic D, Stefanović A, Kotur-Stevuljević J, Zeljković A, Spasojević-Kalimanovska V, Vekić J, Miljković M, Paripović D, Peco-Antić A, Jelić-Ivanović Z. Association of Myeloperoxidase and the Atherogenic Index of Plasma in Children with End-Stage Renal Disease. J Med Biochem 2017; 36:23-31. [PMID: 28680346 PMCID: PMC5471656 DOI: 10.1515/jomb-2016-0027] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2016] [Accepted: 09/29/2016] [Indexed: 12/31/2022] Open
Abstract
BACKGROUND The aim of this study was to explore oxidative stress status, especially the enzyme myeloperoxidase in children with end-stage renal disease. Also, we investigated possible associations between the atherogenic index of plasma and these parameters. METHODS Lipid status parameters, oxidative stress status parameters, and myeloperoxidase concentration were measured in the sera of 20 children in the last stage of chronic renal disease (ESRD) and 35 healthy children of matching age and sex. The Atherogenic Index of Plasma (AIP) was calculated according to the appropriate equation. RESULTS We did not find any significant differences in myeloperoxidase concentrations between the investigated groups (p=0.394). Oxidative stress parameters were, however, significantly higher in the patient group (p<0.001), as well as the atherogenic index of plasma (p<0.001). Myeloperoxidase concentration and advanced oxidation protein product (AOPP) concentration were independently associated with increased AIP in the patient group (p<0.05). CONCLUSIONS Changes in AIP in children with ERSD are associated with the oxidative stress status and myeloper-oxidase concentration.
Collapse
Affiliation(s)
- Danijela Ristovski-Kornic
- Health Center Pančevo, Serbia
- Danijela Ristovski Kornic Health Center Pančevo, Serbia Miloša Obrenovića 4-6 26000 Pančevo, Phone: (+38164)158-34-34 Serbia e-mail:
| | - Aleksandra Stefanović
- Department of Medical Biochemistry, Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia
| | - Jelena Kotur-Stevuljević
- Department of Medical Biochemistry, Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia
| | - Aleksandra Zeljković
- Department of Medical Biochemistry, Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia
| | | | - Jelena Vekić
- Department of Medical Biochemistry, Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia
| | - Milica Miljković
- Department of Medical Biochemistry, Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia
| | - Dušan Paripović
- Department of Nephrology, University Children’s Hospital, Belgrade, Serbia
| | - Amira Peco-Antić
- Department of Nephrology, University Children’s Hospital, Belgrade, Serbia
- Medical Faculty, University of Belgrade, Belgrade, Serbia
| | - Zorana Jelić-Ivanović
- Department of Medical Biochemistry, Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia
| |
Collapse
|
86
|
Myeloperoxidase Attenuates Pathogen Clearance during Plasmodium yoelii Nonlethal Infection. Infect Immun 2016; 85:IAI.00475-16. [PMID: 27795354 DOI: 10.1128/iai.00475-16] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2016] [Accepted: 10/06/2016] [Indexed: 01/23/2023] Open
Abstract
Myeloperoxidase (MPO), a leukocyte-derived enzyme mainly secreted by activated neutrophils, is known to be involved in the immune response during bacterial and fungal infection and inflammatory diseases. Nevertheless, the role of MPO in a parasitic disease like malaria is unknown. We hypothesized that MPO contributes to parasite clearance. To address this hypothesis, we used Plasmodium yoelii nonlethal infection in wild-type and MPO-deficient mice as a murine malaria model. We detected high MPO plasma levels in wild-type mice with Plasmodium yoelii infection. Unexpectedly, infected MPO-deficient mice did not show increased parasite loads but were able to clear the infection more rapidly than wild-type mice. Additionally, the presence of neutrophils at the onset of infection seemed not to be essential for the control of the parasitemia. The effect of decreased parasite levels in MPO-deficient mice was absent from animals lacking mature T and B cells, indicating that this effect is most likely dependent on adaptive immune response mechanisms. Indeed, we observed increased gamma interferon and tumor necrosis factor alpha production by T cells in infected MPO-deficient mice. Together, these results suggest that MPO modulates the adaptive immune response during malaria infection, leading to an attenuated parasite clearance.
Collapse
|
87
|
Ahmad W, Jantan I, Kumolosasi E, Bukhari SNA. Standardized extract of Tinospora crispa stimulates innate and adaptive immune responses in Balb/c mice. Food Funct 2016; 7:1380-9. [PMID: 26839149 DOI: 10.1039/c5fo01531f] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Standardized extract of Tinospora crispa has been shown to exhibit immunostimulatory effects on innate immune responses in Wistar-Kyoto rats by enhancing neutrophil and T cell-mediated immunity. In this study the immunostimulatory effects of T. crispa were further investigated on the cellular immune response by determining its effect on nitric oxide (NO) production ability, peritoneal macrophage phagocytosis and delayed type hypersensitivity (DTH), whereas the humoral immune response was evaluated through the measurement of serum immunoglobulins (IgG and IgM) and serum lysozyme levels. Male Balb/c mice were immunized with 200 μL of 5 × 10(9) sheep red blood cells (sRBCs) per mL on day 0 and orally administered with 50, 100 and 200 mg per kg of ethanol extract of T. crispa for 14 days. Syringin and magnoflorine were qualitatively and quantitatively analyzed in the extract as chemical markers by using a validated reversed-phase high performance liquid chromatography method. T. crispa extract (TCE) considerably improved the peritoneal macrophages' ability to engulf FITC-labeled E. coli in a dose-dependent manner. TCE also dose-dependently promoted NO production in peritoneal macrophages activated by a lipopolysaccharide (LPS) and markedly potentiated the sRBS-induced swelling rate of the mice paw in DTH. The extract significantly enhanced the level of serum immunoglobulins, showing maximum activity at 100 mg kg(-1). Compared to the control groups, the serum lysozyme level and myeloperoxidase (MPO) activity were significantly higher in extract-treated groups. These findings suggest that T. crispa possesses strong immunostimulatory activities and might act as a natural immunomodulator as well as a potential nutraceutical for the modulation of the immune response.
Collapse
Affiliation(s)
- Waqas Ahmad
- Drug and Herbal Research Centre, Faculty of Pharmacy, Universiti Kebangsaan Malaysia, Jalan Raja Muda Abdul Aziz, 50300 Kuala Lumpur, Malaysia.
| | - Ibrahim Jantan
- Drug and Herbal Research Centre, Faculty of Pharmacy, Universiti Kebangsaan Malaysia, Jalan Raja Muda Abdul Aziz, 50300 Kuala Lumpur, Malaysia.
| | - Endang Kumolosasi
- Drug and Herbal Research Centre, Faculty of Pharmacy, Universiti Kebangsaan Malaysia, Jalan Raja Muda Abdul Aziz, 50300 Kuala Lumpur, Malaysia.
| | - Syed Nasir Abbas Bukhari
- Drug and Herbal Research Centre, Faculty of Pharmacy, Universiti Kebangsaan Malaysia, Jalan Raja Muda Abdul Aziz, 50300 Kuala Lumpur, Malaysia.
| |
Collapse
|
88
|
Azarsız E, Karaca N, Levent E, Kutukculer N, Sozmen E. Chitotriosidase enzyme activity: is this a possible chronic inflammation marker in children with common variable immunodeficiency and early atherosclerosis? Ann Clin Biochem 2016; 54:636-643. [PMID: 27705887 DOI: 10.1177/0004563216675647] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
Background Common variable immunodeficiency is a rare clinically symptomatic primary immunodeficiency disorder which manifests a wide variability of symptoms, complications. Atherosclerosis in common variable immunodeficiency patients has not been investigated yet contrary to other severe clinical complications. We aimed to investigate the chitotriosidase enzyme's role as an inflammation and atherosclerosis marker in paediatric common variable immunodeficiency patients. Methods Common variable immunodeficiency patients (n = 24) and healthy controls (n = 23) evaluated for chitotriosidase activity with other inflammation markers (hsCRP, myeloperoxidase, serum amyloid A, ferritin), lipid profile and echocardiographic findings (carotid artery intima media thickness - cIMT, brachial artery flow-mediated vazodilatation - FMD%). Results In patients, the mean chitotriosidase activity (8.98 ± 6.28) was significantly higher than the controls (5.17 ± 3.42) ( P = 0.014). Chitotriosidase showed positive relation with hs-CRP ( P = 0.011) and SAA ( P = 0.011) but had no relation with ferritin ( P = 0.155), HDL ( P = 0.152) or LDL-cholesterol ( P = 0.380). Mean cIMT increased in patients compared with the controls ( P < 0.001) but did not show any relation with chitotriosidase ( P = 0.546). FMD% decreased in patients ( P < 0.001) also showing no relation with chitotriosidase ( P = 0.298). Ventricular myocardial performance indexes had no significant difference, but RVEF% decreased in patients ( P = 0.043). Conclusions High chitotriosidase activity in common variable immunodeficiency patients demonstrated in vivo the presence of activated macrophages indicating ongoing inflammation. Echocardiographic diastolic functional deficiency, increased cIMT and decreased FMD% may be accepted as early atherosclerotic findings, but none of them showed relationship with chitotriosidase activities.
Collapse
Affiliation(s)
- Elif Azarsız
- 1 Department of Pediatrics, Pediatric Biochemistry, Faculty of Medicine, Ege University, Izmir, Turkey
| | - Neslihan Karaca
- 2 Department of Pediatric Immunology, Faculty of Medicine, Ege University, Izmir, Turkey
| | - Erturk Levent
- 3 Department of Pediatric Cardiology, Faculty of Medicine, Ege University, Izmir, Turkey
| | - Necil Kutukculer
- 2 Department of Pediatric Immunology, Faculty of Medicine, Ege University, Izmir, Turkey
| | - Eser Sozmen
- 4 Department of Biochemistry, Faculty of Medicine, Ege University, Izmir, Turkey
| |
Collapse
|
89
|
Exogenous Ghrelin Accelerates the Healing of Acetic Acid-Induced Colitis in Rats. Int J Mol Sci 2016; 17:ijms17091455. [PMID: 27598133 PMCID: PMC5037734 DOI: 10.3390/ijms17091455] [Citation(s) in RCA: 42] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2016] [Revised: 08/18/2016] [Accepted: 08/26/2016] [Indexed: 02/07/2023] Open
Abstract
Previous studies have shown that ghrelin reduces colonic inflammation induced by trinitrobenzene sulfonic acid and dextran sodium sulfate. In the present study we determined the effect of treatment with ghrelin on the course of acetic acid-induced colitis in rats. Rectal administration of 3% acetic acid solution led to induction of colitis in all animals. Damage of the colonic wall was accompanied by an increase in mucosal concentration of pro-inflammatory interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α), as well mucosal activity of myeloperoxidase. Moreover, induction of colitis led to a reduction in colonic blood flow and DNA synthesis. Administration of ghrelin after induction of colitis led to faster regeneration of the colonic wall and reduction in colonic levels of IL-1β, TNF-α, and myeloperoxidase. In addition, treatment with ghrelin improved mucosal DNA synthesis and blood flow. Our study disclosed that ghrelin exhibits a strong anti-inflammatory and healing effect in acetic acid-induced colitis. Our current observation in association with previous findings that ghrelin exhibits curative effect in trinitrobenzene sulfonic acid- and dextran sodium sulfate-induced colitis suggest that therapeutic effect of ghrelin in the colon is universal and independent of the primary cause of colitis.
Collapse
|
90
|
Myeloperoxidase-Oxidized LDLs Enhance an Anti-Inflammatory M2 and Antioxidant Phenotype in Murine Macrophages. Mediators Inflamm 2016; 2016:8249476. [PMID: 27656049 PMCID: PMC5021486 DOI: 10.1155/2016/8249476] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2016] [Revised: 07/28/2016] [Accepted: 08/02/2016] [Indexed: 12/02/2022] Open
Abstract
Macrophages and oxidized LDLs play a key role in atherogenesis but their heterogeneity has been neglected up to now. Macrophages are prone to polarization and subsets of polarized macrophages have been described in atheromas. LDLs can be oxidized not only chemically by copper (Ox-LDLs) but also enzymatically by myeloperoxidase (MpOx-LDLs) resulting in oxidized LDLs poor in lipid peroxides. The effects of physiologically relevant myeloperoxidase-oxidized LDLs on macrophage polarization or on polarized macrophages remain largely unknown. In this study, the effects of LDLs on macrophage polarization were investigated by monitoring the expression of M1 and M2 genes following stimulation with native LDLs, Ox-LDLs, or MpOx-LDLs in RAW 264.7 cells. Except for MRC1, which is induced only by Ox-LDLs, MpOx-LDLs induced an overexpression of most of the selected marker genes at the mRNA level. MpOx-LDLs also modulate marker gene expression in polarized macrophages favoring notably anti-inflammatory Arg1 expression in M2 cells and also in the other phenotypes. Noteworthy, MpOx-LDLs were the most efficient to accumulate lipids intracellularly in (un)polarized macrophages whatever the phenotype. These data were largely confirmed in murine bone marrow-derived macrophages. Our data suggest that MpOx-LDLs were the most efficient to accumulate within cells and to enhance an anti-inflammatory and antioxidant phenotype in M2 cells and also in the other macrophage phenotypes.
Collapse
|
91
|
Kim H, Wei Y, Lee JY, Wu Y, Zheng Y, Moskowitz MA, Chen JW. Myeloperoxidase Inhibition Increases Neurogenesis after Ischemic Stroke. J Pharmacol Exp Ther 2016; 359:262-272. [PMID: 27550713 DOI: 10.1124/jpet.116.235127] [Citation(s) in RCA: 40] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2016] [Accepted: 08/19/2016] [Indexed: 01/08/2023] Open
Abstract
The relationship between inflammation and neurogenesis in stroke is currently not well understood. Focal ischemia enhances cell proliferation and neurogenesis in the neurogenic regions, including the subventricular zone (SVZ), dentate gyrus, as well as the non-neurogenic striatum, and cortex in the ischemic hemisphere. Myeloperoxidase (MPO) is a potent oxidizing enzyme secreted during inflammation by activated leukocytes, and its enzymatic activity is highly elevated after stroke. In this study, we investigated whether the inhibition of MPO activity by a specific irreversible inhibitor, 4-aminobenzoic acid hydrazide (ABAH) (MPO-/- mice) can increase neurogenesis after transient middle cerebral artery occlusion in mice. ABAH administration increased the number of proliferating bromodeoxyuridine (BrdU)-positive cells expressing markers for neural stems cells, astrocytes, neuroprogenitor cells (Nestin), and neuroblasts (doublecortin) in the ischemic SVZ, anterior SVZ, striatum, and cortex. MPO inhibition also increased levels of brain-derived neurotrophic factor, phosphorylation of cAMP response element-binding protein (Ser133), acetylated H3, and NeuN to promote neurogenesis in the ischemic SVZ. ABAH treatment also increased chemokine CXC receptor 4 expression in the ischemic SVZ. MPO-deficient mice treated with vehicle or ABAH both showed similar effects on the number of BrdU+ cells in the ischemic hemisphere, demonstrating that ABAH is specific to MPO. Taken together, our results underscore a detrimental role of MPO activity to postischemia neurogenesis and that a strategy to inhibit MPO activity can increase cell proliferation and improve neurogenesis after ischemic stroke.
Collapse
Affiliation(s)
- HyeonJu Kim
- Center for Systems Biology and Institute for Innovation in Imaging (H.K., J.Y.L., J.W.C), and Neuroscience Center (Y. Wei, Y. Wu, Y.Z., M.A.M.), Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
| | - Ying Wei
- Center for Systems Biology and Institute for Innovation in Imaging (H.K., J.Y.L., J.W.C), and Neuroscience Center (Y. Wei, Y. Wu, Y.Z., M.A.M.), Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
| | - Ji Yong Lee
- Center for Systems Biology and Institute for Innovation in Imaging (H.K., J.Y.L., J.W.C), and Neuroscience Center (Y. Wei, Y. Wu, Y.Z., M.A.M.), Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
| | - Yue Wu
- Center for Systems Biology and Institute for Innovation in Imaging (H.K., J.Y.L., J.W.C), and Neuroscience Center (Y. Wei, Y. Wu, Y.Z., M.A.M.), Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
| | - Yi Zheng
- Center for Systems Biology and Institute for Innovation in Imaging (H.K., J.Y.L., J.W.C), and Neuroscience Center (Y. Wei, Y. Wu, Y.Z., M.A.M.), Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
| | - Michael A Moskowitz
- Center for Systems Biology and Institute for Innovation in Imaging (H.K., J.Y.L., J.W.C), and Neuroscience Center (Y. Wei, Y. Wu, Y.Z., M.A.M.), Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
| | - John W Chen
- Center for Systems Biology and Institute for Innovation in Imaging (H.K., J.Y.L., J.W.C), and Neuroscience Center (Y. Wei, Y. Wu, Y.Z., M.A.M.), Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
| |
Collapse
|
92
|
Nagarajan R, Miller CS, Dawson D, Al-Sabbagh M, Ebersole JL. Cross-talk between clinical and host-response parameters of periodontitis in smokers. J Periodontal Res 2016; 52:342-352. [PMID: 27431617 DOI: 10.1111/jre.12397] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/25/2016] [Indexed: 12/14/2022]
Abstract
BACKGROUND AND OBJECTIVE Periodontal diseases are a major public health concern leading to tooth loss and have also been shown to be associated with several chronic systemic diseases. Smoking is a major risk factor for the development of numerous systemic diseases, as well as periodontitis. While it is clear that smokers have a significantly enhanced risk for developing periodontitis leading to tooth loss, the population varies regarding susceptibility to disease associated with smoking. This investigation focused on identifying differences in four broad sets of variables, consisting of: (i) host-response molecules; (ii) periodontal clinical parameters; (iii) antibody responses to periodontal pathogens and oral commensal bacteria; and (iv) other variables of interest, in a population of smokers with (n = 171) and without (n = 117) periodontitis. MATERIAL AND METHODS Bayesian network structured learning (BNSL) techniques were used to investigate potential associations and cross-talk between the four broad sets of variables. RESULTS BNSL revealed two broad communities with markedly different topology between the populations of smokers, with and without periodontitis. Confidence of the edges in the resulting network also showed marked variations within and between the periodontitis and nonperiodontitis groups. CONCLUSION The results presented validated known associations and discovered new ones with minimal precedence that may warrant further investigation and novel hypothesis generation. Cross-talk between the clinical variables and antibody profiles of bacteria were especially pronounced in the case of periodontitis and were mediated by the antibody response profile to Porphyromonas gingivalis.
Collapse
Affiliation(s)
- R Nagarajan
- Division of Biomedical Informatics, College of Medicine, University of Kentucky, Lexington, KY, USA
| | - C S Miller
- Center for Oral Health Research, College of Dentistry, University of Kentucky, Lexington, KY, USA.,Department of Oral Health Practice, Division of Oral Medicine, College of Dentistry, University of Kentucky, Lexington, KY, USA
| | - D Dawson
- Center for Oral Health Research, College of Dentistry, University of Kentucky, Lexington, KY, USA.,Department of Oral Health Practice, Division of Periodontics, College of Dentistry, University of Kentucky, Lexington, KY, USA
| | - M Al-Sabbagh
- Department of Oral Health Practice, Division of Periodontics, College of Dentistry, University of Kentucky, Lexington, KY, USA
| | - J L Ebersole
- Center for Oral Health Research, College of Dentistry, University of Kentucky, Lexington, KY, USA.,Department of Oral Health Practice, Division of Periodontics, College of Dentistry, University of Kentucky, Lexington, KY, USA
| |
Collapse
|
93
|
Amantea D, Certo M, Petrelli F, Bagetta G. Neuroprotective Properties of a Macrolide Antibiotic in a Mouse Model of Middle Cerebral Artery Occlusion: Characterization of the Immunomodulatory Effects and Validation of the Efficacy of Intravenous Administration. Assay Drug Dev Technol 2016; 14:298-307. [PMID: 27392039 DOI: 10.1089/adt.2016.728] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023] Open
Abstract
Repurposing the macrolide antibiotic azithromycin has recently been suggested as a promising neuroprotective strategy for the acute treatment of ischemic stroke. Here, we aim at further characterizing the immunomodulatory properties of intraperitoneal (i.p.) administration of this drug and, more importantly, at assessing whether neuroprotection can also be achieved by the more clinically relevant intravenous (i.v.) route of administration in a mouse model of focal cerebral ischemia induced by transient (30-min) middle cerebral artery occlusion (MCAo). A single i.p. injection of azithromycin (150 mg/kg) upon reperfusion prevented ischemia-induced spleen contraction and increased the number of MAC-1-immunopositive microglia/macrophages in the ischemic hemisphere 48 h after the insult. This was paralleled by an elevation of alternatively activated phenotypes (i.e., Ym1-immunopositive M2-polarized cells) and by a reduced expression of the pro-inflammatory marker myeloperoxidase. More importantly, i.v. administration of azithromycin upon reperfusion reduced MCAo-induced infarct volume and cerebral edema to an extent comparable to that obtained via the i.p. route. Although the i.p. route is often used for research purposes, it is impractical in the clinical setting; however, i.v. administration can easily be used in ischemic stroke patients who usually have i.v. access already established on hospital admission. The neuroprotective efficacy of the clinically relevant i.v. administration of azithromycin, together with its beneficial immunomodulatory properties reported in mice subjected to transient MCAo, suggests that this macrolide antibiotic can be effectively repurposed for the acute treatment of ischemic stroke. To this end, further work is needed to validate the efficacy of azithromycin in the clinical setting.
Collapse
Affiliation(s)
- Diana Amantea
- 1 Section of Preclinical and Translational Pharmacology, Department of Pharmacy, Health and Nutritional Sciences, University of Calabria , Rende (CS), Italy
| | - Michelangelo Certo
- 1 Section of Preclinical and Translational Pharmacology, Department of Pharmacy, Health and Nutritional Sciences, University of Calabria , Rende (CS), Italy
| | - Francesco Petrelli
- 1 Section of Preclinical and Translational Pharmacology, Department of Pharmacy, Health and Nutritional Sciences, University of Calabria , Rende (CS), Italy
| | - Giacinto Bagetta
- 1 Section of Preclinical and Translational Pharmacology, Department of Pharmacy, Health and Nutritional Sciences, University of Calabria , Rende (CS), Italy .,2 University Consortium for Adaptive Disorders and Head Pain (UCADH), Section of Neuropharmacology of Normal and Pathological Neuronal Plasticity, University of Calabria , Rende, Italy
| |
Collapse
|
94
|
Ray RS, Katyal A. Myeloperoxidase: Bridging the gap in neurodegeneration. Neurosci Biobehav Rev 2016; 68:611-620. [PMID: 27343997 DOI: 10.1016/j.neubiorev.2016.06.031] [Citation(s) in RCA: 65] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2016] [Revised: 06/20/2016] [Accepted: 06/21/2016] [Indexed: 10/21/2022]
Abstract
Neurodegenerative conditions present a group of complex disease pathologies mostly due to unknown aetiology resulting in neuronal death and permanent neurological disability. Any undesirable stress to the brain, disrupts homeostatic balance, through a remarkable convergence of pathophysiological changes and immune dysregulation. The crosstalk between inflammatory and oxidative mechanisms results in the release of neurotoxic mediators apparently spearheaded by myeloperoxidase derived from activated microglia, astrocytes, neurons as well as peripheral inflammatory cells. These isolated entities combinedly have the potential to flare up and contribute significantly to neuropathology and disease progression. Recent, clinicopathological evidence support the association of myeloperoxidase and its cytotoxic product, hypochlorous acid in a plethora of neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, Amyotrophic lateral sclerosis, Multiple sclerosis, Stroke, Epilepsy etc. But the biochemical and mechanistic insights into myeloperoxidase mediated neuroinflammation and neuronal death is still an uncharted territory. The current review outlines the emerging recognition of myeloperoxidase in neurodegeneration, which may offer novel therapeutic and diagnostic targets for neurodegenerative disorders.
Collapse
Affiliation(s)
- R S Ray
- Dr. B.R. Ambedkar Center for Biomedical Research (ACBR), University of Delhi, North Campus, Delhi 110 007, India.
| | - Anju Katyal
- Dr. B.R. Ambedkar Center for Biomedical Research (ACBR), University of Delhi, North Campus, Delhi 110 007, India.
| |
Collapse
|
95
|
Marcondes Sari MH, Souza ACG, Rosa SG, Chagas PM, da Luz SCA, Rodrigues OED, Nogueira CW. Biochemical and histological evaluations of anti-inflammatory and antioxidant p-chloro-selenosteroid actions in acute murine models of inflammation. Eur J Pharmacol 2016; 781:25-35. [DOI: 10.1016/j.ejphar.2016.03.051] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2015] [Revised: 03/23/2016] [Accepted: 03/29/2016] [Indexed: 12/27/2022]
|
96
|
Ilangkovan M, Jantan I, Mesaik MA, Bukhari SNA. Inhibitory Effects of the Standardized Extract ofPhyllanthus amaruson Cellular and Humoral Immune Responses in Balb/C Mice. Phytother Res 2016; 30:1330-8. [DOI: 10.1002/ptr.5633] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2016] [Revised: 04/04/2016] [Accepted: 04/08/2016] [Indexed: 12/17/2022]
Affiliation(s)
- Menaga Ilangkovan
- Drug and Herbal Research Center, Faculty of Pharmacy; Universiti Kebangsaan Malaysia; Jalan Raja Muda Abdul Aziz 50300 Kuala Lumpur Malaysia
| | - Ibrahim Jantan
- Drug and Herbal Research Center, Faculty of Pharmacy; Universiti Kebangsaan Malaysia; Jalan Raja Muda Abdul Aziz 50300 Kuala Lumpur Malaysia
| | - Mohamed Ahmed Mesaik
- Tabuk Medical College; University of Tabuk; P.O. Box 741 Tabuk 71491 Saudi Arabia
| | - Syed Nasir Abbas Bukhari
- Drug and Herbal Research Center, Faculty of Pharmacy; Universiti Kebangsaan Malaysia; Jalan Raja Muda Abdul Aziz 50300 Kuala Lumpur Malaysia
| |
Collapse
|
97
|
Abstract
Neutrophils are essential for killing bacteria and other microorganisms, and they also have a significant role in regulating the inflammatory response. Stimulated neutrophils activate their NADPH oxidase (NOX2) to generate large amounts of superoxide, which acts as a precursor of hydrogen peroxide and other reactive oxygen species that are generated by their heme enzyme myeloperoxidase. When neutrophils engulf bacteria they enclose them in small vesicles (phagosomes) into which superoxide is released by activated NOX2 on the internalized neutrophil membrane. The superoxide dismutates to hydrogen peroxide, which is used by myeloperoxidase to generate other oxidants, including the highly microbicidal species hypochlorous acid. NOX activation occurs at other sites in the cell, where it is considered to have a regulatory function. Neutrophils also release oxidants, which can modify extracellular targets and affect the function of neighboring cells. We discuss the identity and chemical properties of the specific oxidants produced by neutrophils in different situations, and what is known about oxidative mechanisms of microbial killing, inflammatory tissue damage, and signaling.
Collapse
Affiliation(s)
- Christine C Winterbourn
- Centre for Free Radical Research, Department of Pathology, University of Otago, Christchurch 8011, New Zealand; , ,
| | - Anthony J Kettle
- Centre for Free Radical Research, Department of Pathology, University of Otago, Christchurch 8011, New Zealand; , ,
| | - Mark B Hampton
- Centre for Free Radical Research, Department of Pathology, University of Otago, Christchurch 8011, New Zealand; , ,
| |
Collapse
|
98
|
Schink M, Leipold E, Schirmeyer J, Schönherr R, Hoshi T, Heinemann SH. Reactive species modify NaV1.8 channels and affect action potentials in murine dorsal root ganglion neurons. Pflugers Arch 2016; 468:99-110. [PMID: 26383867 PMCID: PMC5165275 DOI: 10.1007/s00424-015-1735-z] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2015] [Revised: 08/29/2015] [Accepted: 09/07/2015] [Indexed: 01/10/2023]
Abstract
Dorsal root ganglion (DRG) neurons are important relay stations between the periphery and the central nervous system and are essential for somatosensory signaling. Reactive species are produced in a variety of physiological and pathophysiological conditions and are known to alter electric signaling. Here we studied the influence of reactive species on the electrical properties of DRG neurons from mice with the whole-cell patch-clamp method. Even mild stress induced by either low concentrations of chloramine-T (10 μM) or low-intensity blue light irradiation profoundly diminished action potential frequency but prolonged single action potentials in wild-type neurons. The impact on evoked action potentials was much smaller in neurons deficient of the tetrodotoxin (TTX)-resistant voltage-gated sodium channel NaV1.8 (NaV1.8(-/-)), the channel most important for the action potential upstroke in DRG neurons. Low concentrations of chloramine-T caused a significant reduction of NaV1.8 peak current and, at higher concentrations, progressively slowed down inactivation. Blue light had a smaller effect on amplitude but slowed down NaV1.8 channel inactivation. The observed effects were less apparent for TTX-sensitive NaV channels. NaV1.8 is an important reactive-species-sensitive component in the electrical signaling of DRG neurons, potentially giving rise to loss-of-function and gain-of-function phenomena depending on the type of reactive species and their effective concentration and time of exposure.
Collapse
Affiliation(s)
- Martin Schink
- Center for Molecular Biomedicine, Department of Biophysics, Friedrich Schiller University Jena & Jena University Hospital, Hans-Knöll-Str. 2, 07745, Jena, Germany
| | - Enrico Leipold
- Center for Molecular Biomedicine, Department of Biophysics, Friedrich Schiller University Jena & Jena University Hospital, Hans-Knöll-Str. 2, 07745, Jena, Germany
| | - Jana Schirmeyer
- Center for Molecular Biomedicine, Department of Biophysics, Friedrich Schiller University Jena & Jena University Hospital, Hans-Knöll-Str. 2, 07745, Jena, Germany
| | - Roland Schönherr
- Center for Molecular Biomedicine, Department of Biophysics, Friedrich Schiller University Jena & Jena University Hospital, Hans-Knöll-Str. 2, 07745, Jena, Germany
| | - Toshinori Hoshi
- Department of Physiology, University of Pennsylvania, Philadelphia, PA, USA
| | - Stefan H Heinemann
- Center for Molecular Biomedicine, Department of Biophysics, Friedrich Schiller University Jena & Jena University Hospital, Hans-Knöll-Str. 2, 07745, Jena, Germany.
| |
Collapse
|
99
|
Tiyerili V, Camara B, Becher MU, Schrickel JW, Lütjohann D, Mollenhauer M, Baldus S, Nickenig G, Andrié RP. Neutrophil-derived myeloperoxidase promotes atherogenesis and neointima formation in mice. Int J Cardiol 2015; 204:29-36. [PMID: 26655530 DOI: 10.1016/j.ijcard.2015.11.128] [Citation(s) in RCA: 51] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/03/2015] [Accepted: 11/20/2015] [Indexed: 11/26/2022]
Abstract
BACKGROUND Myeloperoxidase (MPO), expressed mainly in neutrophils, is an enzyme linked to inflammation and oxidative stress. MPO is an independent prognostic marker in healthy individuals as well as in patients with coronary artery disease. In this present study we analyze the role of MPO in experimental atherogenesis and neointima formation after vascular injury in mice. METHODS AND RESULTS 6-8 weeks old apolipoprotein E-deficient (ApoE(-/-)) mice were fed a high-cholesterol diet for 8 weeks with concomitant treatment with two different doses (10 μg/mg bw vs. 20 μg/mg bw) of 4-ABAH (MPO inhibitor). Application at lower dosage did not affect oxidative stress, endothelial function and atherosclerotic plaque development. 4-ABAH in higher dosage decreased inflammatory markers and vascular oxidative stress, consecutively improved endothelial function and reduced significantly atherosclerotic plaque development. To assess the role of circulating intracellular MPO, irradiated ApoE(-/-) mice were repopulated with bone marrow-derived cells from MPO(-/-) mice and were fed a high-cholesterol diet for 8 weeks. This MPO deficiency resulted in alleviated inflammation, reduced oxidative stress and improved endothelial function with a significant impact on plaque formation. To understand the possible role of MPO in vascular remodeling, we tested its effects on neointima formation following vascular injury in mice. MPO inhibition by 4-ABAH reduced significantly neointima formation. It was significantly reduced in MPO deficient mice, whereas transfer of spleen-derived neutrophils from WT mice enhanced it. CONCLUSION Our data suggests a central role of MPO in the pathogenesis of atherogenesis and prefers pharmacological MPO inhibition as a therapeutic strategy for prevention and therapy of atherosclerosis and restenosis.
Collapse
Affiliation(s)
- Vedat Tiyerili
- Department of Cardiology, University of Bonn, Bonn, Germany.
| | - Bakary Camara
- Department of Cardiology, University of Bonn, Bonn, Germany
| | - Marc U Becher
- Department of Cardiology, University of Bonn, Bonn, Germany
| | | | - Dieter Lütjohann
- Institute for Clinical Chemistry, University of Bonn, Bonn, Germany
| | - Martin Mollenhauer
- Department of Cardiology, Heart Center, University of Cologne, Cologne, Germany
| | - Stephan Baldus
- Department of Cardiology, Heart Center, University of Cologne, Cologne, Germany
| | - Georg Nickenig
- Department of Cardiology, University of Bonn, Bonn, Germany
| | - René P Andrié
- Department of Cardiology, University of Bonn, Bonn, Germany
| |
Collapse
|
100
|
Panagopoulos V, Zinonos I, Leach DA, Hay SJ, Liapis V, Zysk A, Ingman WV, DeNichilo MO, Evdokiou A. Uncovering a new role for peroxidase enzymes as drivers of angiogenesis. Int J Biochem Cell Biol 2015; 68:128-38. [PMID: 26386352 DOI: 10.1016/j.biocel.2015.09.006] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2015] [Revised: 09/01/2015] [Accepted: 09/16/2015] [Indexed: 10/23/2022]
Abstract
Peroxidases are heme-containing enzymes released by activated immune cells at sites of inflammation. To-date their functional role in human health has mainly been limited to providing a mechanism for oxidative defence against invading bacteria and other pathogenic microorganisms. Our laboratory has recently identified a new functional role for peroxidase enzymes in stimulating fibroblast migration and collagen biosynthesis, offering a new insight into the causative association between inflammation and the pro-fibrogenic events that mediate tissue repair and regeneration. Peroxidases are found at elevated levels within and near blood vessels however, their direct involvement in angiogenesis has never been reported. Here we report for the first time that myeloperoxidase (MPO) and eosinophil peroxidase (EPO) are readily internalised by human umbilical vein endothelial cells (HUVEC) where they promote cellular proliferation, migration, invasion, and stimulate angiogenesis both in vitro and in vivo. These pro-angiogenic effects were attenuated using the specific peroxidase inhibitor 4-ABAH, indicating the enzyme's catalytic activity is essential in mediating this response. Mechanistically, we provide evidence that MPO and EPO regulate endothelial FAK, Akt, p38 MAPK, ERK1/2 phosphorylation and stabilisation of HIF-2α, culminating in transcriptional regulation of key angiogenesis pathways. These findings uncover for the first time an important and previously unsuspected role for peroxidases as drivers of angiogenesis, and suggest that peroxidase inhibitors may have therapeutic potential for the treatment of angiogenesis related diseases driven by inflammation.
Collapse
Affiliation(s)
- Vasilios Panagopoulos
- School of Medicine, Discipline of Surgery, Basil Hetzel Institute, University of Adelaide, Adelaide, SA, Australia
| | - Irene Zinonos
- School of Medicine, Discipline of Surgery, Basil Hetzel Institute, University of Adelaide, Adelaide, SA, Australia
| | - Damien A Leach
- School of Medicine, Discipline of Surgery, Basil Hetzel Institute, University of Adelaide, Adelaide, SA, Australia
| | - Shelley J Hay
- School of Medicine, Discipline of Surgery, Basil Hetzel Institute, University of Adelaide, Adelaide, SA, Australia
| | - Vasilios Liapis
- School of Medicine, Discipline of Surgery, Basil Hetzel Institute, University of Adelaide, Adelaide, SA, Australia
| | - Aneta Zysk
- School of Medicine, Discipline of Surgery, Basil Hetzel Institute, University of Adelaide, Adelaide, SA, Australia
| | - Wendy V Ingman
- School of Medicine, Discipline of Surgery, Basil Hetzel Institute, University of Adelaide, Adelaide, SA, Australia
| | - Mark O DeNichilo
- School of Medicine, Discipline of Surgery, Basil Hetzel Institute, University of Adelaide, Adelaide, SA, Australia
| | - Andreas Evdokiou
- School of Medicine, Discipline of Surgery, Basil Hetzel Institute, University of Adelaide, Adelaide, SA, Australia.
| |
Collapse
|